https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--940da3ee2393a73dcd97397366b2af21/quality-attribute-considerations-for-chewable-tablets-guidance-for-industry2026-10-13T07:14:17.478Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--93e45d9cdc138a0587a46c5d73ea5ce5/refuse-to-file-nda-and-bla-submissions-to-cder-guidance-for-industry2026-10-13T07:14:14.549Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--937c241ca88869017e77f8ac4615c5da/review-of-fdas-implementation-of-the-drug-export-amendments-of-19862026-10-13T07:14:10.600Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--8297d645da6e9f470a0a141a976190b4/compliance-policy-for-limited-modifications-to-certain-marketed-tobacco-products-guidance-for-indust2026-10-13T07:14:09.433Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--8317f7485fa2337975cdf4ca02f40c9e/guidance-for-industry-recommendations-for-the-assessment-of-donor-suitability-and-blood-product-safe2026-10-13T07:14:09.433Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--8b5c661c1ba9696e12146842d2e456aa/metered-dose-inhaler-mdi-and-dry-powder-inhaler-dpi-drug-products-quality-considerations2026-10-13T07:14:08.004Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_ii/appendix-ii2026-10-13T07:14:06.425Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--92a5de1e83e18db0d4fd797e1f976871/nonallergic-rhinitis-developing-drug-products-for-treatment2026-10-13T07:14:06.167Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--92d3abae790227e0c1b01bf62f7a1c43/cpg-sec-525625-whole-and-ground-pepper-adulteration-with-insect-and-rodent-filth-mold-mammalian-excr2026-10-13T07:14:06.167Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--9317dd582c3afe02fe1aebee212ea0fe/cpg-sec-585225-black-eyed-peas-cow-peas-field-peas-dried-adulteration-with-lygus-bug-damage2026-10-13T07:14:06.167Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--931a506b4b8488e7347944bad7866700/cpg-sec-480300-lack-of-expiration-date-of-stability-data2026-10-13T07:14:06.167Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--8232cfe3cfcac7b9c1c4cd737df1bd3f/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for2026-10-13T07:14:04.618Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--75ffa20783d21f32e4b17c3127d7da92/submission-of-premarket-notifications-for-magnetic-resonance-diagnostic-devices-guidance-for-industr2026-10-13T07:14:04.084Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--92430773ad4eea4d7f3ea9c3c6bfecc0/s3a-guidance-note-for-guidance-on-toxicokinetics-the-assessment-of-systemic-exposure-in-toxicity-stu2026-10-13T07:14:01.902Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--924a6e57b95d1c31a920cd010edd0b50/transition-plan-for-medical-devices-issued-emergency-use-authorizations-euas-related-to-coronavirus2026-10-13T07:14:01.902Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_i/appendix-i2026-10-13T07:14:01.799Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--75dd23828d5d14aed0bd6e0445a8d1ff/pat-a-framework-for-innovative-pharmaceutical-development-manufacturing-and-quality-assurance-guidan2026-10-13T07:14:01.473Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--8a582a8577889b61aa34b8c8bd1f344c/court-decisions-anda-approvals-and-180-day-exclusivity-under-the-hatch-waxman-amendments-to-the-fede2026-10-13T07:14:00.132Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--8a7a4b8b8964a9483d7b1f6e016e190b/q4b-annex-5-disintegration-test-general-chapter2026-10-13T07:14:00.132Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--81db2d161165005091d7d3ac4a438740/dscsa-standards-for-the-interoperable-exchange-of-information-for-tracing-of-certain-human-finished2026-10-13T07:13:59.857Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--751c3650b3533c2d62d09995541c5d93/establishing-effectiveness-and-safety-for-hormonal-drug-products-intended-to-prevent-pregnancy-guida2026-10-13T07:13:58.717Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7581e3e57f272869eb24d4b78c5dca69/cpg-sec-525375-whole-ginger-adulteration-with-insect-filth-mold-mammalian-excreta2026-10-13T07:13:58.717Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--75db709cd5264ec60ba83fed607b7654/consumer-antiseptic-wash-final-rule-questions-and-answers-guidance-for-industry2026-10-13T07:13:58.717Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--9227720a08c80f13d92719c7eb11c87b/cvm-gfi-239-human-food-by-products-for-use-as-animal-food2026-10-13T07:13:57.876Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_900/9002026-10-13T07:13:56.634Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--819da1bc2ebbc669231382f91a24b86d/bioavailability-and-bioequivalence-studies-for-nasal-aerosols-and-nasal-sprays-for-local-action2026-10-13T07:13:56.385Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--748e443a51088db0886e04ce56227d51/risk-evaluation-and-mitigation-strategies-modifications-and-revisions-guidance-for-industry2026-10-13T07:13:55.665Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--67e72e0a24571c8fbbf9429e089d823d/user-fees-and-refunds-for-premarket-notification-submissions-510ks-guidance-for-industry-and-food-an2026-10-13T07:13:52.779Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--745a30be487cf5e15b6ef0958ec9fe9f/instructions-for-use-patient-labeling-for-human-prescription-drug-and-biological-products-content-an2026-10-13T07:13:52.574Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--897348613a894b0f17ea87c69fb0a96d/qualification-of-biomarker-plasma-fibrinogen-in-studies-examining-exacerbations-andor-all-cause-mort2026-10-13T07:13:51.970Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--89a7923a60460bf521d3d7a75f9d2db9/failure-to-respond-to-an-anda-complete-response-letter-within-the-regulatory-timeframe-guidance-for2026-10-13T07:13:51.970Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--81906bc1b6ccd486b7ecaa73c4dec5c3/certificates-of-confidentiality-guidance-for-sponsors-sponsor-investigators-researchers-industry-and2026-10-13T07:13:51.362Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--8198315ec558e54cb42ea46ad0e94dc4/providing-submissions-in-electronic-format-postmarketing-safety-reports-for-vaccines-guidance-for-in2026-10-13T07:13:51.362Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--677a115faeece4a6cc25b42e4c83bcd8/size-of-beads-in-drug-products-labeled-for-sprinkle-rev1-guidance-for-industry2026-10-13T07:13:50.092Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--742b21872eade89145b527b8057fcc1a/grandfathering-policy-for-packages-and-homogenous-cases-of-product-without-a-product-identifier2026-10-13T07:13:49.100Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7432adf0057de316bf2f85ecdef9be26/class-ii-and-iiia-laser-light-show-projectors-and-shows-laser-notice-402026-10-13T07:13:49.100Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--815609ceee18d4b948a5b35cc315c002/release-of-ora-laboratory-analytical-results-to-the-responsible-party-guidance-for-food-and-drug-adm2026-10-13T07:13:47.131Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--815b8dc93d168d1a3e2f1ecf1c0eaaa8/m4s-the-ctd-safety-appendices2026-10-13T07:13:47.131Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--73ca77a9f8c9469282dc06a570c7d83e/guidance-for-the-development-of-vaginal-contraceptive-drugs-nda2026-10-13T07:13:46.547Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--73e72682bc219afe345093e3ea0e3f0e/class-ii-special-controls-guidance-document-serological-assays-for-the-detection-of-beta-glucan-pdf2026-10-13T07:13:46.547Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--738cae5fa88d352f3aac64e28f06e426/field-alert-report-submission-questions-and-answers-guidance-for-industry-guidance-for-industry2026-10-13T07:13:41.338Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--736574d1209cbc2106f0b205ff675c5b/human-gene-therapy-for-hemophilia-guidance-for-industry2026-10-13T07:13:37.612Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--896b6e2cb67f80e96cddbc987fc5514c/compounded-drug-products-that-are-essentially-copies-of-a-commercially-available-drug-product-under2026-10-13T07:13:36.349Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--80e9acd3b5cf34c135a3d794d1b732c0/size-shape-and-other-physical-attributes-of-generic-tablets-and-capsules2026-10-13T07:13:36.091Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--814a878cd6dbc7be1761474f04d788c4/implanted-brain-computer-interface-bci-devices-for-patients-with-paralysis-or-amputation-non-clinica2026-10-13T07:13:36.091Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--66ee2c045db6f6288f94ec56e6afb687/vulvovaginal-candidiasis-developing-drugs-for-treatment2026-10-13T07:13:35.521Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--671b83aaa51acedd310d0119d2767162/q10-pharmaceutical-quality-system2026-10-13T07:13:35.521Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--72c5a6243ae353df43c30123d2a5c679/cpg-sec-590400-natural-bristle-brushes-ie-hair-brushes-shaving-brushes-nit-contamination2026-10-13T07:13:33.355Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--72ee831f53255f508615233fab91c33d/labeling-for-combined-hormonal-contraceptives-guidance-for-industry2026-10-13T07:13:33.355Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--8910572680ed663270f9cea54954e51f/cross-labeling-oncology-drugs-in-combination-regimens2026-10-13T07:13:31.939Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--895bbea09d04481b0d8141dc7f493688/clinical-trial-imaging-endpoint-process-standards-guidance-for-industry2026-10-13T07:13:31.939Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_800/8002026-10-13T07:13:31.728Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--66881d42c4cf2e7951e11f63d6284f00/chronic-hepatitis-d-virus-infection-developing-drugs-for-treatment-guidance-for-industry2026-10-13T07:13:30.595Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--80922518e743e0186cd6d8518b379f16/integration-of-dose-counting-mechanisms-into-mdi-drug-products2026-10-13T07:13:29.941Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--80b70ccdf51f790480ad75eaa5891508/revising-anda-labeling-following-revision-of-the-rld-labeling-guidance-for-industry-guidance-for-ind2026-10-13T07:13:29.941Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--728fcb52965f7b95f6cfa434273cd3dc/cvm-gfi-223-small-entity-compliance-guide-declaring-color-additives-in-animal-foods2026-10-13T07:13:29.225Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--72ada78ff9dfcbae0ead7ca483d229af/cpg-sec-550100-apple-butter-adulteration-with-mold-rodent-filth-insect2026-10-13T07:13:29.225Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--72b33608b9ff1749e9aa96afd0614059/studying-multiple-versions-of-a-cellular-or-gene-therapy-product-in-an-early-phase-clinical-trial-gu2026-10-13T07:13:29.225Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--662ebbe0701d1cd5e7870629c4daf2cd/user-fees-for-513g-requests-for-information-guidance-for-industry-and-food-and-drug-administration-s2026-10-13T07:13:28.084Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6673ba5cb95452b95adf34c48b3050f0/integrated-summaries-of-effectiveness-and-safety-location-within-the-common-technical-document2026-10-13T07:13:28.084Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--806020809f65c448af1cd4afd8169984/estrogen-and-estrogenprogestin-drug-products-to-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atro2026-10-13T07:13:27.095Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--808fabe11dae9a7602cfdc5500267b1f/efficacy-studies-to-support-marketing-of-fibrin-sealant-products-manufactured-for-commercial-use-gui2026-10-13T07:13:27.095Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--890a5bc29241bf4841128c6c27cedf1a/helicobacter-pylori-associated-duodenal-ulcer-disease-in-adults-developing-drugs-for-treatment2026-10-13T07:13:26.750Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6628a6d6ef80fb22afbbe8dabfa9b9a6/community-acquired-bacterial-pneumonia-developing-drugs-for-treatment2026-10-13T07:13:25.250Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--65f7dcc87de3651bc636259521bde1ee/new-and-revised-draft-qandas-on-biosimilar-development-and-the-bpci-act-revision-4-draft-guidance-fo2026-10-13T07:13:21.817Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--72003607932c33950f77951ae715b7e8/cvm-gfi-259-vich-gl58-stability-testing-of-new-veterinary-drug-substances-and-medicinal-products-in2026-10-13T07:13:20.911Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--724bd54386edecf87022dbed65922d96/recommendations-for-microbial-vectors-used-for-gene-therapy-guidance-for-industry2026-10-13T07:13:20.911Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--88ec6ee0c8c139435d4d2a986e8fa9bc/e14-and-s7b-clinical-and-nonclinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-pot2026-10-13T07:13:19.414Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--803a9ad24cba9bc8057fd09db6f4f290/botanical-drug-development-guidance-for-industry2026-10-13T07:13:18.687Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7180e8835efd00eafafec3caa44dde7d/labeling-otc-human-drug-products-updating-labeling-in-rlds-and-andas2026-10-13T07:13:16.850Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--71d66845eb90374edf46bffcf36e743a/interpreting-sameness-of-monoclonal-antibody-products-under-the-orphan-drug-regulations2026-10-13T07:13:16.850Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--8005ff3954824bd46f4a452cf2e5398b/same-surgical-procedure-exception-under-21-cfr-127115b-questions-and-answers-regarding-the-scope-of2026-10-13T07:13:13.054Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--70ef5fb61d4c85bdc48be386cc97c141/considerations-for-the-inclusion-of-adolescent-patients-in-adult-oncology-clinical-trials2026-10-13T07:13:10.452Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--70f85380e566db6f28f4f533100bd9d0/guidance-for-industry-consultation-procedures-under-fdas-1992-statement-of-policy-for-foods-derived2026-10-13T07:13:10.452Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--711099c2c759d76f1b90088fb8364067/pediatric-study-plans-content-of-and-process-for-submitting-initial-pediatric-study-plans-and-amende2026-10-13T07:13:10.452Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_700/7002026-10-13T07:13:09.392Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7fc2832f152f8e20380247ff354a0ff8/bioanalytical-method-validation-guidance-for-industry2026-10-13T07:13:06.709Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7f555581c3a9c2f8978fce2a4ac8cc30/investigational-in-vitro-diagnostics-in-oncology-trials-streamlined-submission-process-for-study-ris2026-10-13T07:13:00.947Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7f748282dc0be5aa4ae83de7f887a28c/recommended-approaches-to-integration-of-genetic-toxicology-study-results2026-10-13T07:13:00.947Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7f87f7468bd6d0c84c0a34c57a38fe5d/industry-supported-scientific-and-educational-activites2026-10-13T07:13:00.947Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6578abce29366dab592f554c9fa66341/evaluation-of-internal-standard-responses-during-chromatographic-bioanalysis-questions-and-answers2026-10-13T07:12:58.527Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6596c588b59e3a9dd7824929f90e9989/premenopausal-women-with-breast-cancer-developing-drugs-for-treatment-guidance-for-industry2026-10-13T07:12:58.527Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--65b9c37a7c8fe18509dcc903e520ab0d/guide-for-establishing-and-maintaining-a-calibration-constancy-intercomparison-system-for-microwave2026-10-13T07:12:58.527Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7f53b2e0123d85292db07b57785f7606/e2bm-data-elements-for-transmission-of-individual-case-safety-reports2026-10-13T07:12:56.226Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--70d43dfd4f3555e1e285832719a43c63/format-and-content-of-the-clinical-and-statistical-sections-of-an-application2026-10-13T07:12:54.404Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--653ac2b27530b969c61a53d62ab8e2fa/use-of-serological-tests-to-reduce-the-risk-of-transmission-of-trypanosoma-cruzi-infection-in-blood2026-10-13T07:12:54.271Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--88be8291f5317695ba7635d4c9a19807/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-for-over-the2026-10-13T07:12:53.841Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7eecfb3b2ddcbe9015775acb662e7d44/requirements-for-transactions-with-first-responders-under-section-582-of-the-federal-food-drug-and-c2026-10-13T07:12:52.136Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--64d29abd2cd7520993381b9fe6bd85ee/restricted-delivery-systems-flow-restrictors-for-oral-liquid-drug-products-guidance-for-industry2026-10-13T07:12:49.797Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--65250e160b25e6e5a0eedb61e1964649/guidance-for-industry-providing-regulatory-submissions-to-cber-in-electronic-format-investigational2026-10-13T07:12:49.797Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7dcea8a2ba008fe49aa7e3ab8bfdc762/medication-guides-adding-a-toll-free-number-for-reporting-adverse-events2026-10-13T07:12:46.720Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7dd8cd6e31a2a08cb6d6682a18bdc08c/antibacterial-drug-products-use-of-noninferiority-studies-to-support-approval2026-10-13T07:12:46.720Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7ddc7e00970b0a7fc101cf09d21683f5/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-ich-regions-annex-14-bacter2026-10-13T07:12:46.720Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--64b519a0493be2c605ef1b274333bd9a/investigational-new-drug-applications-prepared-and-submitted-by-sponsor-investigators2026-10-13T07:12:45.540Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--88a00575769c9ef1a5621a5521f3b2ae/statistical-aspects-of-the-design-analysis-and-interpretation-of-chronic-rodent-carcinogenicity-stud2026-10-13T07:12:43.138Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--64789b58105bb55d48fc0a31df511730/calcium-dtpa-and-zinc-dtpa-drug-products-submitting-a-new-drug-application2026-10-13T07:12:40.105Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--64af60a509dfb13b38b9bc15cf3b9416/requests-for-reconsideration-at-the-division-level-under-gdufa2026-10-13T07:12:40.105Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--64649dfe14e5a05185ed213b216be866/s6-r1-addendum-preclinical-safety-evaluation-of-biotechnology-derived-pharmaceuticals2026-10-13T07:12:32.568Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--64739175178e59908737cde8477533b7/q2b-validation-of-analytical-procedures-methodology2026-10-13T07:12:32.568Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7d7875b6b46bb3ac954d91d591dd831a/cvm-gfi-76-questions-and-answers-bse-feed-regulations2026-10-13T07:12:29.839Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7dc629875652aa113d506dc0a9826d37/planning-for-the-effects-of-high-absenteeism-to-ensure-availability-of-medically-necessary-drug-prod2026-10-13T07:12:29.839Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--883879ad25a555a327b3646b5de5c4b0/cpg-sec-398350-regulatory-actions-against-assemblers-of-x-ray-equipment-that-fail-to-file-reports-of2026-10-13T07:12:23.172Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--886d05a7938b3ccf1c6b2c4530291b95/nonclinical-evaluation-of-endocrine-related-drug-toxicity2026-10-13T07:12:23.172Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--88842805f00d36018728a23a1b252304/pulmonary-tuberculosis-developing-drugs-for-treatment2026-10-13T07:12:23.172Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--70c6776d8ae8a2bb0f18da200f6faa6d/nucleic-acid-testing-nat-for-human-immunodeficiency-virus-type-1-hiv-1-and-hepatitis-c-virus-hcv-tes2026-10-13T07:12:22.185Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7cd7a65fb48b17bcab4fafce2e077fec/carcinogenicity-study-protocol-submissions2026-10-13T07:12:15.795Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7d43791636b7dbb6e2da93398fbf60a2/cpg-sec-570425-tree-nuts-adulteration-involving-rejects-insect-infestation-moldy-rancid-otherwise-de2026-10-13T07:12:15.795Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7d65c809ff3849bea099cd1b267c4a53/s1br1-addendum-to-s1b-testing-for-carcinogenicity-of-pharmaceuticals-guidance-for-industry2026-10-13T07:12:15.795Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--88187e206a96d6e7082c546a3c78eadc/fees-exceed-the-costs-waivers-under-the-prescription-drug-user-fee-act2026-10-13T07:12:15.092Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7067225a3b6d3e6dd278df669aa9ffb8/ich-q12-implementation-considerations-for-fda-regulated-products-draft-guidance-for-industry2026-10-13T07:12:13.864Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--63ce31dcb2ae0354ecfe821173f7fe79/cvm-gfi-243-vich-gl56-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in2026-10-13T07:12:11.562Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--641a8f7f29cb1a5830ae00add9263b35/the-deemed-to-be-a-license-provision-of-the-bpci-act-questions-and-answers-guidance-for-industry2026-10-13T07:12:11.562Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--87e825c1b5c0d756a035c229913829fe/cpg-sec-590300-direct-reference-authority-for-pseudomonas-contamination-of-cosmetics-used-in-the-eye2026-10-13T07:12:08.443Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--880f945b0230d103a2e91c3cfe73db32/master-protocols-efficient-clinical-trial-design-strategies-to-expedite-development-of-oncology-drug2026-10-13T07:12:08.443Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--639dc25bad10185ed672d0af24c6267f/advanced-prostate-cancer-developing-gonadotropin-releasing-hormone-analogues-guidance-for-industry-c2026-10-13T07:12:07.012Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--700bc3b13716ac5b027c0a48d652e577/general-guidelines-for-otc-combination-products2026-10-13T07:12:06.917Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--704dfd7a4840bf51048d75e85aadd5f6/assessing-the-irritation-and-sensitization-potential-of-transdermal-and-topical-delivery-systems-for2026-10-13T07:12:06.917Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7cad32ea02a3c56646e87591086eebfe/cpg-sec-525300-condimental-seeds-other-than-fennel-seeds-and-sesame-seeds-adulteration-by-mammalian2026-10-13T07:12:05.777Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7cc77c6b5b6a1df404c374d9d60cc2ad/e2f-development-safety-update-report2026-10-13T07:12:05.777Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--63986ae3e6e013bb11e0be6352a9c5d1/premarket-approval-application-and-humanitarian-device-exemption-modular-review-guidance-for-industr2026-10-13T07:12:04.497Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--87ba9c9303741bb42556933251cd1294/waivers-exceptions-and-exemptions-from-the-requirements-of-section-582-of-the-federal-food-drug-and2026-10-13T07:12:03.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6f9003e43e86b8068d72983e072dc31f/limited-population-pathway-for-antibacterial-and-antifungal-drugs-guidance-for-industry2026-10-13T07:12:03.066Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--634784d3cf44e24344516eda0a28356c/additional-recommendations-for-testing-whole-blood-blood-components-source-plasma-and-source-leukocy2026-10-13T07:12:02.268Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--63908a24d88c5fc5be655f52803ba742/frequently-asked-questions-statement-of-investigator-form-fda-1572-guidance-for-sponsors-clinical-in2026-10-13T07:12:02.268Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7b343fad4cd7e2a93b14484c8a6aa7e6/user-fees-and-refunds-for-de-novo-classification-requests-guidance-for-industry-and-food-and-drug-ad2026-10-13T07:12:00.944Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7c2f13cda219e5686ea040d83459f009/annual-reporting-by-prescription-drug-wholesale-distributors-and-third-party-logistics-providers-que2026-10-13T07:12:00.944Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6f8b1a92d7ebd0f9d45706d4e14786a1/cooperative-manufacturing-arrangements-for-licensed-biologics-guidance-for-industry2026-10-13T07:12:00.876Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--871950754d4d755cf1531ee8079b3e60/adaptive-design-clinical-trials-for-drugs-and-biologics-guidance-for-industry2026-10-13T07:12:00.713Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--62ee7f6d9b5cb792180281dfaa6f9d49/establishing-effectiveness-for-drugs-intended-to-treat-male-hypogonadotropic-hypogonadism-attributed2026-10-13T07:11:58.484Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--630963311e052a0b5acffc534b2f038e/guidance-for-industry-or-m7r2-assessment-and-control-of-dna-reactive-mutagenic-impurities-in-pharmac2026-10-13T07:11:58.484Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6f861b8d44fac4a4fd96204e74e3a0f0/use-of-nucleic-acid-tests-on-pooled-and-individual-samples-from-donors-of-whole-blood-and-blood-comp2026-10-13T07:11:58.378Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6f8a46741906beab385b8d058d332e6c/s9-nonclinical-evaluation-for-anticancer-pharmaceuticals2026-10-13T07:11:58.378Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7ae6799398d585d42441e77472c97a08/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-ich-annex-13-bulk-density-a2026-10-13T07:11:57.409Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--86c4c2e17811f14db5c7c97212b57a4a/submitting-documents-using-real-world-data-and-real-world-evidence-to-fda-for-drug-and-biological-pr2026-10-13T07:11:56.414Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--86d936abe9fa7f0fbbe5d17fba89c38f/investigating-out-of-specification-oos-test-results-for-pharmaceutical-production-level-2-revision-g2026-10-13T07:11:56.414Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6f3ee887013ba0409995b1d73a8d2d58/submission-of-summary-bioequivalence-data-for-abbreviated-new-drug-applications2026-10-13T07:11:56.024Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--7a8865db12d7d91ba632ed3ae3d62ac9/integrated-summary-of-effectiveness2026-10-13T07:11:54.529Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--867b7e46f409252e0206406500a4a8a4/cpg-sec-525600-whole-and-ground-nutmeg-adulteration-with-insect-filth-mold-rodent-filth2026-10-13T07:11:50.149Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--86958e1412409230399f3547a5dfaf77/inds-for-phase-2-and-phase-3-studies-chemistry-manufacturing-and-controls-information-guidance-for-i2026-10-13T07:11:50.149Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--790618304713510ac08b65796391d522/recommendations-for-the-submission-of-loincr-codes-in-regulatory-applications-to-the-us-food-and-dru2026-10-13T07:11:48.741Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_600/6002026-10-13T07:11:48.251Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--62db037e56f16525773d67839acb8dcb/guidance-for-industry-exports-under-the-fda-export-reform-and-enhancement-act-of-1996-guidance-for-i2026-10-13T07:11:46.464Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--85e24e5a2da355141b5e1cc0e3051bb0/s9-nonclinical-evaluation-for-anticancer-pharmaceuticals-questions-and-answers2026-10-13T07:11:41.774Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--861d1144a5af95ea98a876596fc432d1/recommendations-for-donor-screening-with-a-licensed-test-for-hiv-1-antigen-memorandum-to-all-registe2026-10-13T07:11:41.774Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--62b97f9d4db20a6190f432fda5dd8510/recommendations-to-reduce-the-risk-of-transfusion-transmitted-malaria-guidance-for-industry2026-10-13T07:11:37.670Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--78e4fd96ec95e818ed5cfbd46d94faf8/long-term-follow-up-after-administration-of-human-gene-therapy-products-guidance-for-industry2026-10-13T07:11:35.664Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--61f730aea8c139ae8c60552a44927e9b/submitting-study-datasets-for-vaccines-to-the-office-of-vaccines-research-and-review-guidance-for-in2026-10-13T07:11:33.276Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6286ebcac9176f779de82aa00399ec2d/protection-of-human-subjects-categories-of-research-that-may-be-reviewed-by-the-institutional-review2026-10-13T07:11:33.276Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6ed5d73f3e7577e5c17234fc0e850983/phs-guideline-on-infectious-disease-issues-in-xenotransplantation-phs-guideline2026-10-13T07:11:32.681Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6ecd64b664b1a999686b1c804bcd5ca4/development-of-non-opioid-analgesics-for-acute-pain2026-10-13T07:11:14.406Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_500/5002026-10-13T07:11:12.062Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6e2acf58005422b647951e1f766e01df/sample-formats-for-form-fda-356h20112026-10-13T07:11:09.839Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6e8ffeb458ca102798f5d1743a131a1a/denture-base-resins-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-indus2026-10-13T07:11:09.839Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--61cb4e315920d0afded1669965ef9bc5/cvm-gfi-267-biomarkers-and-surrogate-endpoints-in-clinical-studies-to-support-effectiveness-of-new-a2026-10-13T07:11:08.033Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5c8cbd3a836d494d95895f33dff258b8/changes-to-an-approved-nda-or-anda-questions-and-answers-guidance-for-industry2026-10-13T07:11:06.959Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5c9962d767d1a022013de67ab80b5e53/sunscreen-innovation-act-section-586cc-advisory-committee-process2026-10-13T07:11:06.959Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6dce2e72e23f96b85a9ae46da6c4ac23/q11-development-and-manufacture-of-drug-substances-questions-and-answers-chemical-entities-and-biote2026-10-13T07:11:05.352Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--78da6cef601c06d25bebe0749deecc8a/marketing-status-notifications-under-section-506i-of-the-federal-food-drug-and-cosmetic-act2026-10-13T07:11:04.966Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_400/4002026-10-13T07:11:03.679Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5c60c330eca52d3dec154f2178ad2e3c/medical-device-reporting-for-user-facilities2026-10-13T07:11:03.022Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--61c65ca4bc4a4082a156b6b12500b659/process-validation-general-principles-and-practices-guidance-for-industry2026-10-13T07:11:02.672Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5c47cce06d8c83a1da50410300e3ce5c/irritable-bowel-syndrome-clinical-evaluation-of-products-for-treatment2026-10-13T07:10:59.953Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6d2ca07eeb2c21143042f852581cefba/cpg-sec-315100-illegal-interstate-commercial-shipment-of-dentures-cpg-retitled-and-revised-51920052026-10-13T07:10:59.207Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6dcdb9c4e609bdcdcf571ca23e3ac89d/use-of-real-world-evidence-to-support-regulatory-decision-making-for-medical-devices-guidance-for-in2026-10-13T07:10:59.207Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6187f76bc0ec839aa634ae6ad841a0bf/cpg-sec-515700-chocolate-and-chocolate-liquor-adulteration-with-insect-and-rodent-filth2026-10-13T07:10:58.882Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--618a839e98e77705cddb3c5b798f2dd0/referencing-the-definition-of-device-in-the-federal-food-drug-and-cosmetic-act-in-guidance-regulator2026-10-13T07:10:58.882Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--619bc0278a4b77e5bf166a956dcdca25/user-fees-and-refunds-for-premarket-approval-applications-and-device-biologics-license-applications2026-10-13T07:10:58.882Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--78a4a6f98b37ad4a9fc1378f079c8cfa/early-alzheimers-disease-developing-drugs-for-treatment2026-10-13T07:10:58.791Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--78c4588896e7a1c95957ada24fe9d8ce/cpg-sec-545300-foods-rail-car-sanitation-adulteration2026-10-13T07:10:58.791Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--789961fdeb065fba608978e7ca526e5c/guidance-for-industry-bulk-transport-of-juice-concentrates-and-certain-shelf-stable-juices2026-10-13T07:10:56.589Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--60eb326a7cb1b880d4f8785830e76e9f/waiver-of-irb-requirements-for-drug-and-biological-product-studies-guidance-for-sponsors-clinical-in2026-10-13T07:10:54.468Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--60f569f22809c1e3c368ae406f5c6351/certain-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-recovered-from-donors-who-w2026-10-13T07:10:54.468Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--612a50ee0ab3701e8ee293720d46edfd/e8r1-general-considerations-for-clinical-studies2026-10-13T07:10:54.468Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_300/3002026-10-13T07:10:53.455Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5b6f919462174411ab6f4825fc41dbec/container-closure-systems-for-packaging-human-drugs-and-biologics-questions-and-answers-guidance-for2026-10-13T07:10:53.390Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5bb478416e5e4fb8269ebdbd341fdbbc/planning-for-the-effects-of-high-absenteeism-to-ensure-availability-of-medically-necessary-drug-prod2026-10-13T07:10:53.390Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5bc0261eb807dc766684e1c803098d5b/cpg-sec-555250-statement-of-policy-for-labeling-and-preventing-cross-contact-of-common-food-allergen2026-10-13T07:10:53.390Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5bf2e0137337e777c85e6b0801d0aa74/cders-program-for-the-recognition-of-voluntary-consensus-standards-related-to-pharmaceutical-quality2026-10-13T07:10:53.390Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6cd27dcb51a35287496d14c8c9b58c5d/food-effect-bioavailability-and-fed-bioequivalence-studies-guidance-for-industry2026-10-13T07:10:52.836Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6d26ceca931d792d305956546371f002/recurrent-herpes-labialis-developing-drugs-for-treatment-and-prevention2026-10-13T07:10:52.836Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--787fd968f268fc5d20c6cab3d8f76672/enforcement-priorities-for-electronic-nicotine-delivery-system-ends-and-other-deemed-products-on-the2026-10-13T07:10:51.516Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_200/2002026-10-13T07:10:49.206Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--60b203c4efde1c924fc97c7b7c408353/evaluation-of-bulk-drug-substances-nominated-for-use-in-compounding-under-section-503b-of-the-federa2026-10-13T07:10:45.549Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5b438eca5c42d963e6355842addb766a/disclosure-of-materials-provided-to-advisory-committees-in-connection-with-open-advisory-committee-m2026-10-13T07:10:44.795Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5b5c654dcae141527f9144256aa391dd/basic-safety-and-essential-performance-of-medical-electrical-equipment-medical-electrical-systems-an2026-10-13T07:10:44.795Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6cb48a50403ec21ece1a57d2b6ac85de/drug-induced-liver-injury-premarketing-clinical-evaluation2026-10-13T07:10:44.186Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--60af8f1b72383935137d4d80f9742859/circumstances-that-constitute-delaying-denying-limiting-or-refusing-a-drug-or-device-inspection-guid2026-10-13T07:10:42.080Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--780df3811e949a00da1d1d1186bc2a0d/cpg-sec-550270-currants-adulteration-involving-wormy-fruits2026-10-13T07:10:41.303Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--784b995c99ead9009a79cdfbdb891248/upper-facial-lines-developing-botulinum-toxin-drug-products2026-10-13T07:10:41.303Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--78536c8ce5d387bead34075780b81a81/meta-analyses-of-randomized-controlled-clinical-trials-to-evaluate-the-safety-of-human-drugs-or-biol2026-10-13T07:10:41.303Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5addfbcaf0152a8f97592450c140dd40/cvm-gfi-97-vich-gl14-effectiveness-of-anthelmintics-specific-recommendations-for-caprines2026-10-13T07:10:35.037Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5aed6761fb1f9ded5cfe663fb62a5861/cpg-sec-578200-corn-meal-adulteration-by-insect-and-rodent-filth2026-10-13T07:10:35.037Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5b01b7d5f8b03208791c6643d3e9342e/development-of-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality-r2026-10-13T07:10:35.037Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--77f9fc1212731ac8363e8258cbd686b0/use-of-electronic-health-record-data-in-clinical-investigations-guidance-for-industry2026-10-13T07:10:33.087Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--77fd364f8278561c7411e3b6db6f5ca9/s8-immunotoxicity-studies-for-human-pharmaceuticals2026-10-13T07:10:33.087Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_1700/17002026-10-13T07:10:29.904Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5a54640809caf1f19a1ade665d625c62/contact-dermatitis-from-topical-drug-products-for-cutaneous-application-human-safety-assessment-guid2026-10-13T07:10:28.922Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5a71cea68d5035bdc35d51d54419d1d2/cpg-sec-608500-illegal-sales-of-veterinary-prescription-drugs-direct-reference-authority-for-warning2026-10-13T07:10:28.922Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5ad17e9af766fcda580390f67abcb1a0/summary-for-new-drug-and-antibiotic-applications-format-and-content-of-the-summary-for-new-drug-and2026-10-13T07:10:28.922Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6c7964390ca090c281ad4d21c07b091c/marketing-clearance-of-diagnostic-ultrasound-systems-and-transducers-guidance-for-industry-and-food2026-10-13T07:10:28.092Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--77d04ac484c9d1b9a289a0e514405b4f/principles-of-premarket-pathways-for-combination-products-guidance-for-industry-and-fda-staff2026-10-13T07:10:25.742Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--607e52046ce9fdc4761222a3375cee90/cpg-sec-615115-extralabel-use-of-medicated-feeds-for-minor-species2026-10-13T07:10:22.040Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6086fe7bafded1f4e503c7276e49c2d1/good-laboratory-practice-regulations-management-briefings-post-conference-report-aug-1979-guidance-f2026-10-13T07:10:22.040Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6088122d713764d422b51b0e46e87f01/use-of-international-standard-iso-10993-1-biological-evaluation-of-medical-devices-part-1-evaluation2026-10-13T07:10:22.040Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_1600/16002026-10-13T07:10:21.878Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5a1ccb51667369b2890a503331988306/acceptance-review-for-de-novo-classification-requests-guidance-for-industry-and-food-and-drug-admini2026-10-13T07:10:21.396Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6c42e2a159ed5617a6d5143904b1bb31/setting-endotoxin-limits-during-development-of-investigational-oncology-drugs-and-biological-product2026-10-13T07:10:19.285Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6c692f1a60390b32897ad6bf25e69468/validation-and-verification-of-analytical-testing-methods-used-for-tobacco-products2026-10-13T07:10:19.285Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_1500/15002026-10-13T07:10:17.246Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--59e6b741c8659a301b9c967cda9fd246/product-identifiers-under-the-drug-supply-chain-security-act-questions-and-answers-guidance-for-indu2026-10-13T07:10:16.653Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6c3255ae3f49f6259e84b46ce989d592/use-of-electronic-informed-consent-in-clinical-investigations-questions-and-answers-guidance-for-ins2026-10-13T07:10:15.804Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--77186838070582a9c9663372239c491f/addressing-misinformation-about-medical-devices-and-prescription-drugs-questions-and-answers2026-10-13T07:10:14.780Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--59ae56b52cf87aba0bd7116819972de0/assessing-user-fees-under-the-prescription-drug-user-fee-amendments-of-2017-guidance-for-industry-gu2026-10-13T07:10:14.591Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_1400/14002026-10-13T07:10:13.593Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6bdc0d2cf5c55f2fc1af11278e48b482/cpg-sec-575100-pesticide-residues-in-food-and-feed-enforcement-criteria2026-10-13T07:10:13.385Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6bdfd609b576c077cf4bac14c8eaf64f/toll-free-number-labeling-and-related-requirements-for-over-the-counter-and-prescription-drugs-marke2026-10-13T07:10:13.385Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5959aeefbd24d68c96ebe0d68306eb3e/nonclinical-testing-of-orally-inhaled-nicotine-containing-drug-products-guidance-for-industry2026-10-13T07:10:12.602Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--599e086aaf05fc3920978b3e1908dffe/investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects-guidance-fo2026-10-13T07:10:12.602Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6bd0ce387e59e5d2dfe75309f9a8e8d2/q11-development-and-manufacture-of-drug-substances2026-10-13T07:10:08.819Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--58eeac9fe1680c64c6be9201fa0895d6/material-threat-medical-countermeasure-priority-review-vouchers-draft-guidance-for-industry-draft-gu2026-10-13T07:10:07.315Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--58f7bd2d2794142d6d1089a3ba31f67f/analytical-procedures-and-methods-validation-for-drugs-and-biologics2026-10-13T07:10:07.315Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--765ca5d37f8173301e06909c51470ec3/recommendations-for-obtaining-a-labeling-claim-for-communicable-disease-donor-screening-tests-using2026-10-13T07:10:05.886Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--76fb1e057a37b559145bb0799edfe056/pharmacogenomic-data-submissions-companion-guidance2026-10-13T07:10:05.886Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_1300/13002026-10-13T07:10:05.112Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6b98a506625a9a4c6fa0360d0b8f61bc/topical-acne-drug-products-for-over-the-counter-human-use-revision-of-labeling-and-classification-of2026-10-13T07:10:02.832Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--58dfbbfcbfea06e0a60599904c74f3d3/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency2026-10-13T07:10:00.434Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6b3b4be8c339afd509c776a3f8d05465/cmc-postapproval-manufacturing-changes-to-be-documented-in-annual-reports2026-10-13T07:09:58.972Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6034559102049f48e03eb63f3778a224/non-inferiority-clinical-trials2026-10-13T07:09:58.666Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--58828b3f8f437cb7e2e0955d366f26b2/guidance-for-entities-considering-whether-to-register-as-outsourcing-facilities-under-section-503b-o2026-10-13T07:09:55.949Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--58981106e848c275b16b8cf3190446c1/cvm-gfi-197-documenting-electronic-data-files-and-statistical-analysis-programs2026-10-13T07:09:55.949Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_1200/12002026-10-13T07:09:54.218Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6b13be0854fbc7d8ec7ba3d3c9745727/technical-considerations-for-demonstrating-reliability-of-emergency-use-injectors-submitted-under-a2026-10-13T07:09:53.369Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--584372041c914b660dd05b0d3837e9a9/cpg-sec-550300-dates-and-date-material-imported-and-domestic-adulteration-involving-mold-insect-excr2026-10-13T07:09:52.892Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--58624f4dc25929a4878daedadb341437/cvm-gfi-187a-heritable-intentional-genomic-alterations-in-animals-risk-based-approach2026-10-13T07:09:52.892Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6ae3e32885c0a65eddbb9134cf3a225e/sterility-requirement-for-aqueous-based-drug-products-for-oral-inhalation-small-entity-compliance-gu2026-10-13T07:09:47.374Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6b0052f748739ffffe5927815c3f05ae/cpg-sec-550050-draft-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-a-toxin2026-10-13T07:09:47.374Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6b11673540c5b275cc8d2872fc43500e/testing-for-biotin-interference-in-in-vitro-diagnostic-devices-guidance-for-industry2026-10-13T07:09:47.374Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--581f4c3fb46020a332f2762d500a4ecf/attachement-qualification-process-for-drug-development-tools-qualification-of-exacerbations-of-chron2026-10-13T07:09:43.242Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5833ddfb7b28ab757d07491a3f8bb5fd/qualification-process-for-drug-development-tools-guidance-for-industry-and-fda-staff2026-10-13T07:09:43.242Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6a61aa77caf770074206f7518a6a5d04/labeling-otc-human-drug-products-using-a-column-format2026-10-13T07:09:40.053Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6a6745ab34a8da93b984476c17069e09/m4-the-ctd-efficacy-questions-and-answers2026-10-13T07:09:40.053Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--57fdb594b79a871aee7f5aa3d3a9a5c0/s7a-safety-pharmacology-studies-for-human-pharmaceuticals2026-10-13T07:09:37.659Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--57fdcf9226fa70e195c2f80d2e7e8076/e15-pharmacogenomics-definitions-and-sample-coding2026-10-13T07:09:37.659Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--600712d924ad935cc379199a32944d94/q5b-quality-of-biotechnological-products-analysis-of-the-expression-construct-in-cells-used-for-prod2026-10-13T07:09:36.182Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--602d22b5965edc8fd6a8c9732737c3ef/medical-gases-current-good-manufacturing-practice-draft-guidance-for-industry2026-10-13T07:09:36.182Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--69f15742df2dc4c8567ff8068120cb53/nontuberculous-mycobacterial-pulmonary-disease-caused-by-mycobacterium-avium-complex-developing-drug2026-10-13T07:09:34.243Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6a0927120da69b7d53805d5a58d06424/cpg-sec-420100-adulteration-of-drugs-under-section-501b-and-501c-of-the-act-direct-reference-seizure2026-10-13T07:09:34.243Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--6a18cc05ce5ed0c08099352b0968f995/safety-labeling-changes-implementation-of-section-505o4-of-the-federal-food-drug-and-cosmetic-act2026-10-13T07:09:34.243Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4f28d7a6e11fe1caf4edf81128f2be8c/cpg-sec-550655-peaches-canned-misbranding-involving-food-standards2026-10-13T07:09:33.865Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--57b2e10127a9997fe2a7310916e94f32/q5c-quality-of-biotechnological-products-stability-testing-of-biotechnologicalbiological-products2026-10-13T07:09:33.658Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--57b79f05610a50567893c7925e731e15/cvm-gfi-96-vich-gl13-effectiveness-of-anthelmintics-specific-recommendations-for-ovines2026-10-13T07:09:33.658Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_1100/11002026-10-13T07:09:33.395Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4f060e5bdfc6fcc1168ee124425d986c/assessing-covid-19-related-symptoms-in-outpatient-adult-and-adolescent-subjects-in-clinical-trials-o2026-10-13T07:09:32.494Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5789f10205825917cf656bc428613059/data-retention-when-subjects-withdraw-from-fda-regulated-clinical-trials-guidance-for-sponsors-clini2026-10-13T07:09:30.947Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5795531f92504bd48fe55bd27815eb8c/bioresearch-monitoring-technical-conformance-guide2026-10-13T07:09:30.947Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--696db5140661a48c3e595c80f34afa5f/useful-written-consumer-medication-information-cmi2026-10-13T07:09:30.646Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4efe50dba426e7b3237eadee978cb81a/m3r2-nonclinical-safety-studies-for-the-conduct-of-human-clinical-trials-and-marketing-authorization2026-10-13T07:09:28.800Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--69616d16e184ecab534e6a2c9cbf2c86/pharmacogenomic-data-submissions-guidance-for-industry2026-10-13T07:09:28.312Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5737a9777ca87c88b3323e0adf423d95/evaluation-of-devices-used-with-regenerative-medicine-advanced-therapies-guidance-for-industry2026-10-13T07:09:25.575Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--575428717a78ff1f5a94e9098a018b5a/general-clinical-pharmacology-considerations-for-pediatric-studies-of-drugs-including-biological-pro2026-10-13T07:09:25.575Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4ee5909d77a008feff744c223af9e14a/gastroparesis-clinical-evaluation-of-drugs-for-treatment-guidance-for-industry2026-10-13T07:09:25.240Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4ef4295c71101fde3907c3739d3771c9/medication-guides-distribution-requirements-and-inclusion-in-risk-evaluation-and-mitigation-strategi2026-10-13T07:09:25.240Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--68f6cc5f256e0f3a331391ba362d595d/product-identifier-requirements-under-the-drug-supply-chain-security-act-compliance-policy-guidance2026-10-13T07:09:24.374Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--69104a4380d06527e8259d39588b5789/clinical-pharmacogenomics-premarket-evaluation-in-early-phase-clinical-studies-and-recommendations-f2026-10-13T07:09:24.374Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5f81707a774ab5f1b6d84be978afcbb5/public-availability-of-labeling-changes-in-changes-being-effected-supplements2026-10-13T07:09:20.629Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5fedd170f2edfa3f205ef02dc97aef1f/development-and-use-of-risk-minimization-action-plans-guidance-for-industry2026-10-13T07:09:20.629Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--68d36aacf40fdf730f64c72d05a37f99/user-fee-waivers-reductions-and-refunds-for-drug-and-biological-products2026-10-13T07:09:15.994Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--569a229cc880f2bbbf5d4eeeb168ea4f/citizen-petitions-and-petitions-for-stay-of-action-subject-to-section-505q-of-the-federal-food-drug2026-10-13T07:09:14.840Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5f4637415bd132302fd7fc953482b5ea/electronic-submission-of-ind-safety-reports-technical-conformance-guide-guidance-for-industry2026-10-13T07:09:13.052Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4ed266aa03065b3fa74efe32d67cba9e/developing-medical-imaging-drug-and-biological-products-part-3-design-analysis-and-interpretation-of2026-10-13T07:09:11.725Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5efeee913c1b119477c2d17c2b54f646/e19-optimisation-of-safety-data-collection2026-10-13T07:09:06.408Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5f0f904f6b464cc260a2e3f27e692d65/fdas-application-of-statutory-factors-in-determining-when-a-rems-is-necessary2026-10-13T07:09:06.408Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--67f8bd39fe96c0e42c57880b967cae98/obesity-and-overweight-developing-drugs-and-biological-products-for-weight-reduction2026-10-13T07:09:05.907Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4df3b90b69306f72626f27d60002a4cb/recommendations-for-deferral-of-donors-and-quarantine-and-retrieval-of-blood-and-blood-products-in-r2026-10-13T07:09:04.721Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4e24df232b4e491220515c79f6999aa8/format-and-content-of-the-nonclinical-pharmacologytoxicology-section-of-an-application-guidance-for2026-10-13T07:09:04.721Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5eefcd7c9ba5dc68f0e12f785c1b9543/fda-oversight-of-pet-drug-products-questions-and-answers2026-10-13T07:08:55.001Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_1000/10002026-10-13T07:08:52.450Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r48_100/1002026-10-13T07:08:46.294Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4dc394bfcb57df1bb54c584099a195b1/cvm-gfi-218-cell-based-products-for-animal-use2026-10-13T07:08:44.488Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5ece07ad6815cea2d3aeb2f8493b5362/pre-storage-leukocyte-reduction-of-whole-blood-and-blood-components-intended-for-transfusion-final-g2026-10-13T07:08:42.797Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4d9fd5fe9d185351777267db1285ac4b/cpg-sec-545600-cinnamon-flavored-toothpicks2026-10-13T07:08:40.295Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4da49eb9baaa8e255f2f71c6c97cc338/facet-screw-systems-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-indus2026-10-13T07:08:40.295Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4da525be629c7e1d83246cdc62b236ed/type-2-diabetes-mellitus-evaluating-the-safety-of-new-drugs-for-improving-glycemic-control-guidance2026-10-13T07:08:40.295Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--55bc2d87e34d01dd146a8802d153abae/orally-disintegrating-tablets-guidance-for-industry2026-10-13T07:08:39.585Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--55eb2630a2c806dfb764d8d67ee13a69/content-and-format-of-inds-for-phase-1-studies-of-drugs-including-well-characterized-therapeutic-bio2026-10-13T07:08:39.585Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--56112592d3a0bc6f8328818480181019/tablet-scoringnomenclature-labeling-and-data-for-evaluation2026-10-13T07:08:39.585Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--56248473c399164c17c1ba3d3f0b7898/brief-summary-and-adequate-directions-for-use-disclosing-risk-information-in-consumer-directed-print2026-10-13T07:08:39.585Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_intro/intro2026-10-13T07:08:38.704Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--41aa16571c465cf764941bc7b7ccd1c1/residual-drug-in-transdermal-and-related-drug-delivery-systems-guidance-for-industry2026-10-13T07:08:37.524Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--41b2867a27ba0bac780af53bcd0e4db0/cvm-gfi-271-reporting-and-mitigating-animal-drug-shortages2026-10-13T07:08:37.524Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--41be71d38a4a143f28861eb0fc7509d2/best-practices-in-developing-proprietary-names-for-human-prescription-drug-products-guidance-for-ind2026-10-13T07:08:37.524Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4d2e2041d1bb93d39991b1ed4c232b1b/providing-clinical-evidence-of-effectiveness-for-human-drug-and-biological-products2026-10-13T07:08:37.405Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5e368e8a6ba6a4301df4bd1ed42bb467/q13-continuous-manufacturing-of-drug-substances-and-drug-products-guidance-for-industry2026-10-13T07:08:37.234Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--559b1738b03922ec9c4abdcfaa32e5e9/recommendations-for-premarket-notification-510k-submissions-for-nucleic-acid-based-human-leukocyte-a2026-10-13T07:08:34.938Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--55a8a555c4600f569e4307f5bd4f214b/submission-documentation-for-sterilization-process-validation-in-applications-for-human-and-veterina2026-10-13T07:08:34.938Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4b9814ed5128686e67b576c8b826c39e/q4b-annex-i-residue-on-ignitionsulphated-ash-general-chapter2026-10-13T07:08:31.048Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4bf3fa35b291a1a8863f4c166cc8a1a0/individual-product-bioequivalence-recommendations-for-specific-products2026-10-13T07:08:31.048Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4c97e99735b790b09fcb1fbc0154e229/premarket-notification-submissions-for-blood-and-plasma-warmers-guidance-for-fda-reviewers2026-10-13T07:08:31.048Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4d2bb91dedc9fada3dc3f9ce6d764d50/cvm-gfi-209-the-judicious-use-of-medically-important-antimicrobial-drugs-in-food-producing-animals2026-10-13T07:08:31.048Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_index/index2026-10-13T07:08:29.272Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5dfc2afc70ed32d3c65b7063015c157d/role-of-hiv-drug-resistance-testing-in-antiretroviral-drug-development2026-10-13T07:08:28.681Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5475b2310372702ab95058335d236ff0/e1a-the-extent-of-population-exposure-to-assess-clinical-safety-for-drugs-intended-for-long-term-tre2026-10-13T07:08:26.217Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5478f432ab1fd4e7b9165a8d1231cc3e/cpg-sec-545450-pottery-ceramics-import-and-domestic-lead-contamination2026-10-13T07:08:26.217Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--549afdfb7f670760432e57a423c68b9c/cpg-sec-555500-all-food-sanitation-including-bacteriological-inspections-classification-of-establish2026-10-13T07:08:26.217Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5519967e8a18ca2493ceeac7293501fb/drug-master-files-guidance-for-industry2026-10-13T07:08:26.217Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4b1f0686dc5393008b8c9093cced6c88/cpg-sec-525550-mace-adulteration-with-insect-filth-mold-foreign-matter-mammalian-excreta2026-10-13T07:08:23.157Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4b8a4ec6e3d99cda5a1d4db16561ba32/biological-product-deviation-reporting-for-licensed-manufacturers-of-biological-products-other-than2026-10-13T07:08:23.157Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--419fcd96abea06408287298767d80b61/technical-specifications-for-submitting-clinical-trial-data-sets-for-treatment-of-noncirrhotic-nonal2026-10-13T07:08:22.898Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4ac79178dc57388a3d5e4c092876760b/providing-regulatory-submissions-in-electronic-format-certain-human-pharmaceutical-product-applicati2026-10-13T07:08:18.376Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5db064f7de9c1e8c61f77b085b720008/s2r1-genotoxicity-testing-and-data-interpretation-for-pharmaceuticals-intended-for-human-use2026-10-13T07:08:17.411Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5475628f9282f19b50c6449eae2a3302/labeling-for-human-prescription-drug-and-biological-products-implementing-the-plr-content-and-format2026-10-13T07:08:16.803Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--40c24e02396337b596371d1f6817dd24/submitting-and-reviewing-complete-responses-to-clinical-holds-revised2026-10-13T07:08:14.955Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5d4d3afefa1315cb429687393e38c428/regulatory-classification-of-pharmaceutical-co-crystals2026-10-13T07:08:11.314Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5d6d297f298dd7573aa10194d22681c5/policy-for-evaluating-impact-of-viral-mutations-on-covid-19-tests-revised-guidance-for-test-develope2026-10-13T07:08:11.314Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--540bf8b674bc8c1c62ae10da1f9a05d4/systemic-antibacterial-and-antifungal-drugs-susceptibility-test-interpretive-criteria-labeling-for-n2026-10-13T07:08:08.806Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5412711fc93b48426178d6f815bc7b76/cpg-sec-585400-cowpeas-black-eyed-peas-canned-succulent-peas-adulteration-by-insects2026-10-13T07:08:08.806Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--54227d6fa363291613ec8cf1f5530617/manufacturing-site-change-supplements-content-and-submission-guidance-for-industry-and-food-and-drug2026-10-13T07:08:08.806Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--40423a90f3266d1a81b0bf05c652d634/alternate-wording-for-caution-statement-laser-notice-302026-10-13T07:08:08.005Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--40908d116f613dc864f61b03d8e2466e/cpg-sec-560400-imported-milk-and-cream-federal-import-milk-act2026-10-13T07:08:08.005Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4094f4edc0daf484f0a4485cf9f7dbd0/nonprescription-sunscreen-drug-products-format-and-content-of-data-submissions2026-10-13T07:08:08.005Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4a6105c8b25e39d4cf24713dc21f08d9/revised-recommendations-for-red-blood-cell-immunization-programs-for-source-plasma-donors-memorandum2026-10-13T07:08:07.879Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3ff0d95cb3ea2e4fb022f6e8f14ac1f4/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-for-treatment-draf2026-10-13T07:08:03.955Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--402ecd59f33afebe8d8db18b83d6e650/cpg-sec-550685-pineapple-canned-imported-and-domestic-misbranding-involving-food-standards2026-10-13T07:08:03.955Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5cb7c6979e5354485ee11349d8324b6e/cvm-gfi-198-vich-gl45-bracketing-and-matrixing-designs-for-stability-testing-of-new-veterinary-drug2026-10-13T07:08:01.750Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5d452cfe034401d4a869d86d69b73493/cvm-gfi-246-hazard-analysis-and-risk-based-preventive-controls-for-food-for-animals-supply-chain-pro2026-10-13T07:08:01.750Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5344ab19df3e1415e1878d2310555e86/electronic-submission-of-lot-distribution-reports-guidance-for-industry2026-10-13T07:08:01.277Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--534ee8575fec8a77b3124f0a6f71da25/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for2026-10-13T07:08:01.277Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--53cc1773eb6156edabb81d5f335358da/gluten-in-drug-products-and-associated-labeling-recommendations-draft-guidance-for-industry2026-10-13T07:08:01.277Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3f68ac4395e2122d6f0c0fd3616b98e0/compliance-with-section-301-of-the-medical-device-user-fee-and-modernization-act-of-2002-as-amended2026-10-13T07:08:00.808Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--48dd6158798cb7e4b2c32912e665d924/premarket-notification-submissions-for-empty-containers-for-the-collection-and-processing-of-blood-a2026-10-13T07:07:59.725Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--49462986f4b42a2a849a728607ee7709/guidance-for-industry-180-day-exclusivity-questions-and-answers2026-10-13T07:07:59.725Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_ii/appendix-ii2026-10-13T07:07:57.951Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--532a5eb9eb877c3fcf259216878f05cf/post-complete-response-letter-clarification-teleconferences-between-fda-and-anda-applicants-under-gd2026-10-13T07:07:55.773Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--533fa9292fb2df3e9a16a16435e0e376/inborn-errors-of-metabolism-that-use-dietary-management-considerations-for-optimizing-and-standardiz2026-10-13T07:07:55.773Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3eff62e9cb67fcafe6072791a5fde913/arthroscopy-pump-tubing-sets-intended-for-multiple-patient-use-premarket-notification-510k-submissio2026-10-13T07:07:55.612Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_i/appendix-i2026-10-13T07:07:54.040Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--52b39b2ba35e2b4f8c76b96c17d45f97/cvm-gfi-181-blue-bird-medicated-feed-labels2026-10-13T07:07:50.300Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--52c49845c8defa725c4e548cb995e32e/s3a-toxicokinetics-the-assessment-of-systemic-exposure-in-toxicity-studies2026-10-13T07:07:50.300Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_900/9002026-10-13T07:07:49.897Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--48ad138c6864b9e846987c54f3ff3552/cpg-sec-540275-crabmeat-fresh-and-frozen-adulteration-with-filth-involving-the-presence-of-escherich2026-10-13T07:07:48.547Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--48cb36d51b5b92765bd558c338fb22e4/cvm-gfi-83-chemistry-manufacturing-and-controls-changes-to-approved-nadaanada2026-10-13T07:07:48.547Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--524e8ff73c02ff511aa65c765ca488af/cpg-sec-230150-blood-donor-classification-statement-paid-or-volunteer-donor2026-10-13T07:07:45.189Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--47bdedff833cb5a79f52437afc5f53a9/information-sheet-guidance-for-sponsors-clinical-investigators-and-irbs-frequently-asked-questions-s2026-10-13T07:07:43.350Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--47e33b5d47a5c76d836b9bbff6235c5a/e2cr2-periodic-benefit-risk-evaluation-report-questions-and-answers2026-10-13T07:07:43.350Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--524913673409f9c54779b98f40e47fce/unique-device-identification-system-form-and-content-of-the-unique-device-identifier-udi-guidance-fo2026-10-13T07:07:40.939Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--477ac325d53352c640fd7eb264e2f2de/format-and-content-for-the-cmc-section-of-an-annual-report2026-10-13T07:07:39.480Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--47844a4c8fdc2c27d11e0240c3e51874/extending-expiration-dates-of-doxycycline-tablets-and-capsules-in-strategic-stockpiles-guidance-for2026-10-13T07:07:39.480Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3df6768872f38e9a08cf3663d69046eb/study-and-evaluation-of-sex-differences-in-the-clinical-evaluation-of-drugs-guidance-for-industry2026-10-13T07:07:38.107Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3e4d89e65e986184d6a176d7ce89e58d/cpg-sec-550800-standardized-canned-fruit-misbranding-involving-improper-declaration-of-packing-mediu2026-10-13T07:07:38.107Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3ef5c77fa07131a1c5f67ba974a1e6cb/hematologic-malignancies-regulatory-considerations-for-use-of-minimal-residual-disease-in-developmen2026-10-13T07:07:38.107Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--5189bd6768e496c7880d9bf83fc51fc7/e2bm-questions-and-answers2026-10-13T07:07:38.033Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--473b1dba6c0bbe5fff35f5d1037420d4/small-business-nutrition-labeling-exemption-guidance2026-10-13T07:07:36.551Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4772cdb1c556d1aed34b423d0b4cd262/s1cr2-dose-selection-for-carcinogenicity-studies-of-pharmaceuticals2026-10-13T07:07:36.551Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--510eea3e76b0ac79230abfc43fa689aa/cpg-sec-585150-asparagus-canned-or-frozen-adulteration-with-insect-filth2026-10-13T07:07:34.737Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--51438b0a19cca364da07064cc42ca4d1/cvm-gfi-217-evaluating-the-effectiveness-of-anticoccidial-drugs-in-food-producing-animals2026-10-13T07:07:34.737Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--46bb60265436588629e5ef3098083eb1/questions-and-answers-on-biosimilar-development-and-the-bpci-act-guidance-for-industry2026-10-13T07:07:33.998Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4fb4b874cb5afa50b6af3df6bc12b7c9/evaluating-respiratory-symptoms-in-chronic-obstructive-pulmonary-disease-a-patient-reported-outcome2026-10-13T07:07:29.605Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4fdf2118040cc146b25d3532ae875ee8/alternate-source-of-the-active-pharmaceutical-ingredient-in-pending-andas-guidance-for-industry2026-10-13T07:07:29.605Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--508233ed38e7bd7f55a08deb5e1182b7/time-and-extent-applications-for-nonprescription-drug-products2026-10-13T07:07:29.605Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3d9b8ebea46c645a68af46418e52b5ac/cpg-sec-540700-labeling-of-processed-and-blended-seafood-products-made-primarily-with-fish-protein2026-10-13T07:07:29.206Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3dc24c31504c2f84ff37672a02234cca/chronic-hepatitis-b-virus-infection-developing-drugs-for-treatment2026-10-13T07:07:29.206Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--460d8e5d931bea9fb3bb5aaeb5c282b5/donor-deferral-due-to-red-blood-cell-loss-during-collection-of-source-plasma-by-automated-plasmapher2026-10-13T07:07:28.586Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4623a045682ef97439b73422d625cefb/submitting-debarment-certification-statements2026-10-13T07:07:28.586Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--46355f344efb6b3fbde5f6b09193800c/cpg-sec-690300-canned-pet-food-withdrawn-43020192026-10-13T07:07:28.586Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4661f80431e2a6d79a7e6c85d2325b52/prescription-drug-marketing-act-pdma-requirements-questions-and-answers2026-10-13T07:07:28.586Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_800/8002026-10-13T07:07:24.424Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--46029aa3c071f5fbf581d43fc0779e92/pediatric-information-incorporated-into-human-prescription-drug-and-biological-products-labeling-goo2026-10-13T07:07:23.942Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3d2be5e4ee23bd9bec1534c265701023/anda-submissions-refuse-to-receive-for-lack-of-justification-of-impurity-limits-guidance-for-industr2026-10-13T07:07:22.964Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3d333f8306374a14c42cbdd8dd1e413a/user-fee-waivers-for-fdc-and-co-packaged-hiv-drugs-for-pepfar2026-10-13T07:07:22.964Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3d76819e5bdaf3261f883e77c433671c/q1d-bracketing-and-matrixing-designs-for-stability-testing-of-new-drug-substances-and-products2026-10-13T07:07:22.964Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4601949e0aeb7d04157083afef4f9e9d/use-of-liquids-andor-soft-foods-as-vehicles-for-drug-administration-general-considerations-for-selec2026-10-13T07:07:20.926Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3d18787f6b2c71556ab1d0904640f919/considerations-in-demonstrating-interchangeability-with-a-reference-product-guidance-for-industry2026-10-13T07:07:18.303Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--45f09b04cd9f7727ec20c2a45b66f7cb/cvm-gfi-201-secg-for-the-index-of-legally-marketed-unapproved-new-animal-drugs-for-minor-species2026-10-13T07:07:14.506Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3b972bf06a27d9e1506916af3c2accd5/cancer-clinical-trial-eligibility-criteria-patients-with-organ-dysfunction-or-prior-or-concurrent-ma2026-10-13T07:07:10.342Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3c070e1897ef6859b0ada01468c21fd9/cpg-sec-550250-citrus-fruit-juices-canned-adulteration-with-fly-filth-and-mold2026-10-13T07:07:10.342Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3c30eb2f2920985e241509b5ac3c505c/cvm-gfi-98-dioxin-in-anti-caking-agents-in-animal-feed-and-feed-ingredients2026-10-13T07:07:10.342Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3c535fe92aba305e57eb2ef3b70afb12/cpg-sec-525500-leafy-spices-other-than-bay-leaves-whole-oregano-leaves-whole-marjoram-whole-sage-lea2026-10-13T07:07:10.342Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3cd37b9598337ac368b135886fb20f3a/on-the-content-and-format-of-chemistry-manufacturing-and-controls-information-and-establishment-desc2026-10-13T07:07:10.342Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--454e2887f26d0074c2f0791bda2d26c6/self-selection-studies-for-nonprescription-drug-products2026-10-13T07:07:09.679Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--458e293f00de150f0a6b23d31b0cc142/cpg-sec-400100-drugs-human-failure-to-register2026-10-13T07:07:09.679Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--45b21f33fa108efed69f78cd0b1f2ed3/cpg-sec-525425-hops-adulteration-involving-aphid-infestation2026-10-13T07:07:09.679Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--45b6b80632c45caddd99a43e30118b24/cpg-sec-537100-eggs-and-egg-products-frozen-adulteration-involving-decomposition2026-10-13T07:07:09.679Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--45d78827a3fa5b35510cdab0285cfcdb/wholesale-distributor-verification-requirement-for-saleable-returned-drug-product-and-dispenser-veri2026-10-13T07:07:09.679Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3484653e56ff08cb243c844c499e192f/q4b-annex-8-sterility-test-general-chapter2026-10-13T07:07:09.150Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--34c89f9ac3c612f6f8aa579c8c0c68cc/cvm-gfi-235-current-good-manufacturing-practice-requirements-for-food-for-animals2026-10-13T07:07:09.150Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3b0a8ebfbc46125fc8e25d2170a58702/cpg-sec-570300-peanut-butter-adulteration-with-filth-grit2026-10-13T07:07:04.990Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3b6f21b2c0a7fdcdae5804f79fa2fc5c/adverse-reactions-section-of-labeling-for-human-prescription-drug-and-biological-products-content-an2026-10-13T07:07:04.990Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_700/7002026-10-13T07:07:03.994Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--44af465b761b3ef467f8e56cba489de5/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for2026-10-13T07:07:02.962Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--450dc4a43518c94762f40bf83f002e10/identification-labels-for-certain-class-i-laser-products-laser-notice-482026-10-13T07:07:02.962Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--454c961274dbf452773e7a2a2f4d5ed1/quality-control-practices-for-compliance-with-the-federal-laser-performance-standard2026-10-13T07:07:02.962Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--274c920222393c94b3e221a4d0ae97f6/formal-meetings-between-the-fda-and-sponsors-or-applicants-of-bsufa-products-guidance-for-industry2026-10-13T07:07:02.677Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3acb9e05ff4c8f183b6391e4ef088b7d/revised-recommendations-regarding-invalidation-of-test-results-of-licensed-and-510k-cleared-bloodbor2026-10-13T07:07:01.635Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3ad67d130bb2204d61939c746cc4969f/submitting-marketing-applications-according-to-the-ichctd-format-general-considerations-20012026-10-13T07:07:01.635Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3b07adfba59c9b62c4c88c045b0db7fa/providing-regulatory-submissions-in-electronic-format-ind-safety-reports-guidance-for-industry2026-10-13T07:07:01.635Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--343d9fd0c00d62b5259804163673de39/assessing-user-fees-under-the-generic-drug-user-fee-amendments-of-2017-guidance-for-industry2026-10-13T07:07:00.822Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3461b4f73ab140ec07958a425afbfbc9/cvm-gfi-92-vich-gl10r-impurities-in-new-veterinary-drug-substances2026-10-13T07:07:00.822Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--34752decf12d272256b4677fefe8a650/pregnant-women-scientific-and-ethical-considerations-for-inclusion-in-clinical-trials2026-10-13T07:07:00.822Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--26f7f5b623544a8461fe8dddf964d4e5/guidance-for-industry-questions-and-answers-on-haccp-regulation-for-fish-and-fishery-products2026-10-13T07:06:58.681Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--270ee9eacdf7512e1d04ba6827852f5c/s12-nonclinical-biodistribution-considerations-for-gene-therapy-products-guidance-for-industry2026-10-13T07:06:58.681Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3aa7a9439164dfc1c8498f67e58fbfda/regulation-of-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-small-entity-complian2026-10-13T07:06:58.239Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--33f004eb2b6857f48c6b83d308a68a3a/reports-on-the-status-of-postmarketing-study-commitments-implementation-of-section-130-of-the-food-a2026-10-13T07:06:57.545Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3a4e4f0747aea84c41d2bdf2faa822ae/cvm-gfi-214-vich-gl35-pharmacovigilance-of-veterinary-medicinal-products-electronic-standards-for-tr2026-10-13T07:06:54.712Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--26f6d5ef1587aa8c0fb248ecba3e10a8/biocompatibility-testing-of-medical-devices-standards-specific-information-for-the-accreditation-sch2026-10-13T07:06:54.444Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--440dd11fb089438c12e861c781f09b13/small-entity-compliance-guide-declaration-by-name-on-the-label-of-all-foods-and-cosmetic-products-th2026-10-13T07:06:52.092Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--444953cd0142992d8a9c37f3decd5628/pdufa-pilot-project-proprietary-name-review-concept-paper2026-10-13T07:06:52.092Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--33e8a94e8d64a0c75130fd129d690158/compliance-policy-guide-cpg-sec-110650-weekly-entry-filing-guidance-for-industry-and-fda-staff2026-10-13T07:06:51.762Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--33ed0fe20762cb16b4757a810029b6b4/testing-and-labeling-medical-devices-for-safety-in-the-magnetic-resonance-mr-environment-guidance-fo2026-10-13T07:06:51.762Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--39773a29513abcfd656601bf7a3292ee/innovative-approaches-for-nonprescription-drug-products2026-10-13T07:06:45.269Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3a46e0da390354a1abcf2afdcfffd069/fdara-implementation-guidance-for-pediatric-studies-of-molecularly-targeted-oncology-drugs-amendment2026-10-13T07:06:45.269Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--267747c78fba1b7d04374c3281bcea56/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-for-industry2026-10-13T07:06:43.168Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--26da4a9d2f368991755ff95dfc895135/clinical-evaluation-of-general-anesthetics2026-10-13T07:06:43.168Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--26dee3391f6fc1333faa92d6d45a981f/human-immunodeficiency-virus-1-infection-developing-systemic-drug-products-for-pre-exposure-prophyla2026-10-13T07:06:43.168Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--43e4163086bf75b70f63c534550bf999/cpg-sec-335800-clinical-thermometer-adulteration-misbranding-defects2026-10-13T07:06:43.103Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--43eca3a3afa13e01404a5be30a81e4af/self-identification-of-generic-drug-facilities-sites-and-organizations-guidance-for-industry2026-10-13T07:06:43.103Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--43f81d52b8deebc3a9dcc5e5fb84af98/cpg-sec-525250-cloves-adulteration-with-stems2026-10-13T07:06:43.103Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--44013481f256a4cb8a40fd7480a1c3fc/submitting-separate-marketing-applications-and-clinical-data-for-purposes-of-assessing-user-fees-gui2026-10-13T07:06:43.103Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--33d78127ecf555c967b80e92260a47cc/unique-device-identification-system-small-entity-compliance-guide-guidance-for-industry-and-food-and2026-10-13T07:06:42.680Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--396b88bea8e5c53ebb177c822ab78db6/pet-drug-applications-content-and-format-for-ndas-and-andas-attachment-i-sample-formats-for-chemistr2026-10-13T07:06:39.218Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--43c47950246c3bab28ee826ab7d8fa30/qualified-infectious-disease-product-designation-questions-and-answers-guidance-for-industy2026-10-13T07:06:38.536Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--43c54806f4ef92302ef381674497d6af/process-to-request-a-review-of-fdas-decision-not-to-issue-certain-export-certificates-for-devices-gu2026-10-13T07:06:38.536Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--395b07606204b6bb111f31a167044763/mucopolysaccharidosis-type-iii-sanfilippo-syndrome-developing-drugs-for-treatment-guidance-for-indus2026-10-13T07:06:31.667Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--338e0303ab75089f1867401e10611ae0/cpg-sec-550590-cloudberries-multer-berries-canned-adulteration-by-insects2026-10-13T07:06:29.244Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--33b81d837b7a3583909ca549a46e3e9b/e2cr2-periodic-benefit-risk-evaluation-report-pbrer2026-10-13T07:06:29.244Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--25adcdd7f809561433271e29d8440017/andas-stability-testing-of-drug-substances-and-products2026-10-13T07:06:28.601Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--25b602f196f2a0c9fe989db4d6595cce/monoclonal-antibodies-used-as-reagents-in-drug-manufacturing2026-10-13T07:06:28.601Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--261446e9c6bc49ced3e4de64adb2dd8e/comparability-protocols-for-postapproval-changes-to-the-chemistry-manufacturing-and-controls-informa2026-10-13T07:06:28.601Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--437094e7c19b12cbc0ae359109582fbe/cpg-sec-525825-vinegar-definitions-adulteration-with-vinegar-eels2026-10-13T07:06:27.946Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--43970c6ad6b14c0d02dd6ba4d13a4798/streamlining-the-donor-interview-process-recommendations-for-self-administered-questionnaires-guidan2026-10-13T07:06:27.946Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--43b52e1383490a9269887ef0ada20e08/replacement-reagent-and-instrument-family-policy-for-in-vitro-diagnostic-devices-guidance-for-indust2026-10-13T07:06:27.946Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--38e3ae158b4f99ecf7e3267dd28b989a/q3c-maintenance-procedures2026-10-13T07:06:22.319Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3909d6b3ea9fc1591da33b2a6aebe071/m9-biopharmaceutics-classification-system-based-biowaivers2026-10-13T07:06:22.319Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--257194c34f73bdb01213451dd0cf7254/required-warnings-for-cigarette-packages-and-advertisements-small-entity-compliance-guide-revised-gu2026-10-13T07:06:20.028Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3355177a55b1593c55db30df58f2f3f3/reporting-amount-of-listed-drugs-and-biological-products-technical-conformance-guide-guidance-for-in2026-10-13T07:06:19.712Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--429b8808eba1f046bdf3186e440013eb/determining-donor-eligibility-for-autologous-donors-of-blood-and-blood-components-intended-solely-fo2026-10-13T07:06:19.094Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--42f76895ab065fe49315a84ad12d15ca/cpg-sec-675400-rendered-animal-feed-ingredients-withdrawn-43020192026-10-13T07:06:19.094Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--43109aaec2e3c2fe0a3a641b9acc869e/q3c-appendix-52026-10-13T07:06:19.094Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--385be3b8c33274060f9ae9509041e070/chronic-fatigue-syndromemyalgic-encephalomyelitis-developing-drug-products-for-treatment2026-10-13T07:06:17.591Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--38baaf4eb13846a8388a9044310d4fcd/s1a-the-need-for-long-term-rodent-carcinogenicity-studies-of-pharmaceuticals2026-10-13T07:06:17.591Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--24dea18167722a1d95913967e3fe4e97/q4b-annex-6-uniformity-of-dosage-units-general-chapter2026-10-13T07:06:16.383Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2511720ae91695d2d11d92fad3594efa/statistical-information-from-the-june-1999-draft-guidance-and-statistical-information-for-in-vitro-b2026-10-13T07:06:16.383Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--25504eaab433152b69b52560139c96eb/q4b-annex-3-test-for-particulate-contamination-subvisible-particles-general-chapter2026-10-13T07:06:16.383Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--33483d58d3ab5b3f45721d2b2986bfd8/guidance-for-review-staff-and-industry-good-review-management-principles-and-practices-for-pdufa-pro2026-10-13T07:06:15.305Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--24db28e639dca7ae6d4de48421456705/fixed-combinations-and-single-entity-versions-of-previously-approved-antiretrovirals-for-the-treatme2026-10-13T07:06:13.110Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3265288cd8b4d8f7861777cb0d2db107/cpg-sec-525200-capsicum-pods-ground-capsicums-excluding-paprika-ground-paprika-adulteration-with-ins2026-10-13T07:06:10.851Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--330d4a6bb7d391d5bb8e5261d45eacf1/the-use-of-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-for-oral-dru2026-10-13T07:06:10.851Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--42760072c7267226aa42f9614cf01a32/considerations-for-the-use-of-real-world-data-and-real-world-evidence-to-support-regulatory-decision2026-10-13T07:06:10.293Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--243eaa8a0395bc1e1663eedf06400826/unique-device-identification-policy-regarding-compliance-dates-for-class-i-and-unclassified-devices2026-10-13T07:06:09.714Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--382b1e9d9c9fe59a7b838752fe59a16a/facility-definition-under-section-503b-of-the-federal-food-drug-and-cosmetic-act2026-10-13T07:06:09.246Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--38304246c48151b69326e33cd510a7d0/format-and-content-of-a-rems-document-guidance-for-industry2026-10-13T07:06:09.246Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--24053834c489a5943d88cc6e8d3f0ca6/e3-structure-and-content-of-clinical-study-reports-questions-and-answers-r12026-10-13T07:06:07.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--24067d6883593212867aff411e6111ce/fabry-disease-developing-drugs-for-treatment-guidance-for-industry2026-10-13T07:06:07.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--42663748b9f32433cfd70a9992beccc9/ndas-impurities-in-drug-substances2026-10-13T07:06:07.513Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--4270a69815b11dde02b47ac09be63fa3/orally-inhaled-and-intranasal-corticosteroids-evaluation-of-the-effects-on-growth-in-children2026-10-13T07:06:07.513Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--37d33dc8aacf028e197c40204cf70c9e/cpg-sec-250500-plasma-brokers-registration-and-compliance-with-good-manufacturing-practices-is-obsol2026-10-13T07:06:06.047Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--37e881fda953f07b9dfa5ff168f445ed/population-pharmacokinetics-guidance-for-industry2026-10-13T07:06:06.047Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--23a2fe344823926c03a5f347d003ee16/immunogenicity-testing-of-therapeutic-protein-products-developing-and-validating-assays-for-anti-dru2026-10-13T07:06:03.300Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--41ee585fce40636e7735b10be857d169/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment-guidance-for-industry2026-10-13T07:06:03.153Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--375267db02f0aca743e00d896c90687a/determining-whether-to-submit-an-anda-or-a-505b2-application2026-10-13T07:06:00.370Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--325da006e6340e55473bdf48b157e59e/changes-to-an-approved-nda-or-anda-guidance-for-industry2026-10-13T07:05:58.032Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--36c23e240f2feb51a926a9e0f4f24fdc/contents-of-a-complete-submission-for-threshold-analyses-and-human-factors-submissions-to-drug-and-b2026-10-13T07:05:56.530Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--36a741c347d27ba612e261c855e30764/recommendations-for-assessment-of-donor-suitability-and-blood-and-blood-product-safety-in-cases-of-p2026-10-13T07:05:51.997Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--36b7e5dcf2d6e72d3ca906b7f0d5b649/medical-x-ray-imaging-devices-conformance-with-iec-standards-guidance-for-industry-and-food-and-drug2026-10-13T07:05:51.997Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--23684ed49da8b6874af5f958fb155e66/classification-and-requirements-for-laser-illuminated-projectors-lips-laser-notice-no-57-guidance-fo2026-10-13T07:05:50.819Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3164cfa5dd951bfebfbd5ee2186f2afa/cpg-sec-555550-foods-standardized-enriched-or-fortified-adulteration-involving-misbranding-potency2026-10-13T07:05:50.278Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--31d286d69e62cf1726be37adbe102012/ecopy-program-for-medical-device-submissions-guidance-for-industry-and-food-and-drug-administration2026-10-13T07:05:50.278Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2327297b691f0d38b165b99f0edf68e4/principles-for-selecting-developing-modifying-and-adapting-patient-reported-outcome-instruments-for2026-10-13T07:05:47.816Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_600/6002026-10-13T07:05:44.080Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3682141b7d355b25a6b1d696e0f19935/street-drug-alternatives2026-10-13T07:05:43.905Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--368b5288fd249d59b8070c47e300ac87/premarket-notification-submissions-for-transfer-sets-excluding-sterile-connecting-devices-guidance-f2026-10-13T07:05:43.905Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--36a70d578c3071a3b7540369cd89aa2a/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-ind2026-10-13T07:05:43.905Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--30eac9d4fd7275827a6f9080814f232a/cpg-sec-625300-unapproved-new-animal-drugs-follow-up-action-to-approved-warning-letter-direct-refere2026-10-13T07:05:43.774Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--31489c7604e20908b4c7b4ec42a5be0e/postmarketing-studies-and-clinical-trialsimplementation-of-section-505o3-of-the-federal-food-drug-an2026-10-13T07:05:43.774Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--307625d55917824d1fd709731f934df4/pharmaceutical-components-at-risk-for-melamine-contamination-guidance-for-industry2026-10-13T07:05:40.272Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--30b663347d94bfde4f3f3d3dc050f4c7/cpg-sec-480300-lack-of-expiration-date-of-stability-data2026-10-13T07:05:40.272Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--30d5fde929c85070bb02ee0459b259a5/cpg-sec-525330-curry-powder-adulteration-by-insect-and-rodent-filth2026-10-13T07:05:40.272Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--30e91e2d764e5e023d5de63f774ee3ca/media-fills-for-validation-of-aseptic-preparations-for-positron-emission-tomography2026-10-13T07:05:40.272Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--226f86e4f4f7197bbdb2adc9d5398cac/policy-on-maximum-timer-interval-and-exposure-schedule-for-sunlamp-products2026-10-13T07:05:39.216Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--22aa5b30fe5013a70459275e8d3a9c59/drugs-for-the-treatment-of-partial-onset-seizures-extrapolation-of-efficacy-from-adults-to-pediatric2026-10-13T07:05:39.216Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--22b5656c6df9372aae104edaa641901c/considerations-when-transferring-clinical-investigation-oversight-to-another-irb-guidance-for-irbs-c2026-10-13T07:05:39.216Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2fc73a4352b3d23d4942e04ee612bef3/cpg-sec-525225-whole-cassia-or-whole-cinnamon-ground-cinnamon-adulteration-by-insect-and-rodent-filt2026-10-13T07:05:36.675Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2fdb527ac04bdc5384e0913a466410f8/cpg-sec-585675-popcorn-adulteration-with-rodent-filth-and-field-corn2026-10-13T07:05:36.675Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--30034a4ccf7d54e5916691045dbc5367/cpg-sec-300400-contamination-of-devices-labeled-as-sterile2026-10-13T07:05:36.675Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--3040e2581e7e8e0500daccf449bd3bdf/e14-clinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrhy2026-10-13T07:05:36.675Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--35f80f5688b22dd3d6282fde0803bba7/design-and-analysis-of-shedding-studies-for-virus-or-bacteria-based-gene-therapy-and-oncolytic-produ2026-10-13T07:05:34.028Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--35c6fa4ef316628babf372cd02c40726/cvm-gfi-185-vich-gl43-target-animal-safety-for-veterinary-pharmaceutical-products2026-10-13T07:05:30.281Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0f377d0bdc4ca5494cc921b3e22a1ded/sunscreen-innovation-act-withdrawal-of-a-586a-request-or-pending-request-guidance-for-industry2026-10-13T07:05:27.937Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--35c63ae6da589ab37a810449b7b13836/lookback-for-hepatitis-c-virus-hcv-product-quarantine-consignee-notification-further-testing-product2026-10-13T07:05:26.440Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0f16e78e4b83a5cac0c934c54d757b37/hospital-and-health-system-compounding-under-section-503a-of-the-federal-food-drug-and-cosmetic-act2026-10-13T07:05:24.009Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2fb14da41437de7d802e38fece47be2b/human-gene-therapy-for-neurodegenerative-diseases-guidance-for-industry2026-10-13T07:05:23.450Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--21fae9e36260bf5f26514b318b494669/s3b-pharmacokinetics-guidance-for-repeated-dose-tissue-distribution-studies2026-10-13T07:05:23.159Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--22299bd31d11d605a1381110f5151af6/m4er2-the-ctd-efficacy2026-10-13T07:05:23.159Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--351e722aeda5961455eabe12aafa67f3/repackaging-of-certain-human-drug-products-by-pharmacies-and-outsourcing-facilities-guidance-for-ind2026-10-13T07:05:22.681Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2f9d4efbeb679eea6ca3cb821392e522/cvm-gfi-265-use-of-data-from-foreign-investigational-studies-to-support-effectiveness-of-new-animal2026-10-13T07:05:19.944Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0e17fea5982675181be97856d53ee0bc/enforcement-policy-for-face-masks-and-barrier-face-coverings-during-the-coronavirus-disease-covid-192026-10-13T07:05:16.902Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0e948632c7cc557bc413c142464b749e/transition-plan-for-medical-devices-that-fall-within-enforcement-policies-issued-during-the-coronavi2026-10-13T07:05:16.902Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2f61840ad8fa6883261e1f5c1810aed7/e5-ethnic-factors-in-the-acceptability-of-foreign-clinical-data2026-10-13T07:05:16.316Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2f9787b8bed7d331c9ab43c89c3297a6/exculpatory-language-in-informed-consent2026-10-13T07:05:16.316Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2ed90d88e88229b977c1b2f58582ab14/cancer-clinical-trial-eligibility-criteria-brain-metastases2026-10-13T07:05:12.450Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2ee0cb6de18712f19ddd166964dd94dd/q4b-annex-10-polyacrylamide-gel-electrophoresis-general-chapter2026-10-13T07:05:12.450Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2f48063a55f02987a34ef536d1d2de5a/cvm-gfi-207-vich-gl48-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in2026-10-13T07:05:12.450Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0d9a18f52915e3fb3a6217d55d0df673/delayed-graft-function-in-kidney-transplantation-developing-drugs-for-prevention-guidance-for-indust2026-10-13T07:05:11.023Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--21dfc361d8854bd7e331fda627452e54/electronic-source-data-in-clinical-investigations-guidance-for-industry2026-10-13T07:05:10.067Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--21f7ed773e7e58b39afdb011147eb7dc/respiratory-syncytial-virus-infection-developing-antiviral-drugs-for-prophylaxis-and-treatment-guida2026-10-13T07:05:10.067Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_500/5002026-10-13T07:05:08.460Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2ed76ac90991fbcab2f2f1bcf853affe/m4s-the-ctd-safety2026-10-13T07:05:07.402Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0d2f12ae3c0a874bdcd8dccae3018e59/questions-and-answers-or-m7r2-assessment-and-control-of-dna-reactive-mutagenic-impurities-in-pharmac2026-10-13T07:05:06.772Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--21d8c815f36c187837204cc6f48f1e6a/clinical-data-needed-to-support-the-licensure-of-pandemic-influenza-vaccines-guidance-for-industry2026-10-13T07:05:03.742Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0d1e64320d43387f4f720e4ad49bc4db/considerations-for-the-design-of-early-phase-clinical-trials-of-cellular-and-gene-therapy-products-g2026-10-13T07:05:01.862Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2ea8ab9b8e4021cd74f84595be9e68dc/bla-for-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended-for-hemato2026-10-13T07:04:59.584Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_400/4002026-10-13T07:04:59.430Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--21c7cc286b3bbef6fff1faa35807271c/cvm-gfi-241-small-entity-compliance-guide-what-you-need-to-know-about-the-fda-regulation-current-goo2026-10-13T07:04:57.901Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0cd81ead9da55f131fad4e4ba450bb1f/pyrogen-and-endotoxins-testing-questions-and-answers-guidance-for-industry2026-10-13T07:04:54.784Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0cf99174cd25575afac56e97a07b68c7/evaluating-drug-effects-on-the-ability-to-operate-a-motor-vehicle2026-10-13T07:04:54.784Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--21abe0d5306086f5bf31e2066c087325/pregnancy-lactation-and-reproductive-potential-labeling-for-human-prescription-drug-and-biological-p2026-10-13T07:04:51.846Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_300/3002026-10-13T07:04:49.552Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2164219e81b5dcab9816cdd5a4b3f5e5/preparation-of-investigational-new-drug-products-human-and-animal-guidance-for-industry2026-10-13T07:04:48.462Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--217827f9a8f282876d8382ab3a5a1196/cpg-sec-527300-microbial-contaminants-and-alkaline-phosphatase-activity2026-10-13T07:04:48.462Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_200/2002026-10-13T07:04:46.146Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0c7eef6817f60f09d735882e47d3eafb/chapter-48-7348809-bioresearch-monitoring2026-10-13T07:04:45.097Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--20e811bdd1f2ba00591a6ad635f647e4/changes-to-an-approved-application-for-specified-biotechnology-and-specified-synthetic-biological-pr2026-10-13T07:04:43.766Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--20fb34d77ba9dc28034622e32aa0e36e/technical-performance-assessment-of-quantitative-imaging-in-radiological-device-premarket-submission2026-10-13T07:04:43.766Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2e53be1a8cd554f70b44387d65d06827/compliance-policy-for-certain-compounding-of-oral-oxitriptan-5-htp-drug-products-for-patients-with-t2026-10-13T07:04:43.343Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2e6506aae6ea54a273778fb53d56bd8b/container-closure-systems-for-packaging-human-drugs-and-biologics-guidance-for-industry2026-10-13T07:04:43.343Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--20db793d668457423703fe95b7fb9c5f/questions-and-answers-on-quality-related-controlled-correspondence-guidance-for-industry-guidance-fo2026-10-13T07:04:39.812Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--20e2f5caf9d3b9b364e28a261550a489/providing-lot-release-protocol-submissions-to-the-center-for-biologics-evaluation-and-research-cber2026-10-13T07:04:39.812Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0b8a2dc7b27c66474013cd52abb9348f/nonclinical-studies-for-the-safety-evaluation-of-pharmaceutical-excipients2026-10-13T07:04:37.729Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0c4aca6ce7dfd89f826273427accd795/assessing-adhesion-with-transdermal-and-topical-delivery-systems-for-andas-guidance-for-industry2026-10-13T07:04:37.729Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--20c52df00da21ab78474e3dd8b3ae998/male-breast-cancer-developing-drugs-for-treatment-guidance-for-industry2026-10-13T07:04:34.558Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--20c991421ff12f76906226afb91f108e/cvm-gfi-254-donor-eligibility-for-animal-cells-tissues-and-cell-and-tissue-based-products2026-10-13T07:04:34.558Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2e1d3c2d4039e8c2276a885b3c4c4ab7/developing-medical-imaging-drug-and-biological-products-part-1-conducting-safety-assessments2026-10-13T07:04:33.875Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--205fc4817c7b014c3535f12eab6dcc6e/enforcement-policy-for-certain-supplements-for-approved-premarket-approval-pma-or-humanitarian-devic2026-10-13T07:04:30.930Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2df7c074a5e76cf1d45b9484337679a4/fda-regional-implementation-guide-for-e2br3-electronic-transmission-of-individual-case-safety-report2026-10-13T07:04:28.988Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2049e56b0642ade6693139c5105bb418/alcoholism-developing-drugs-for-treatment2026-10-13T07:04:27.683Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_1700/17002026-10-13T07:04:25.907Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2d8480cbeaa6d5a89540d4639db6e84a/recognition-and-use-of-a-standard-for-uniform-blood-and-blood-component-container-labels-guidance-fo2026-10-13T07:04:22.711Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2d9812940b3ea681cd7b13793a595e15/cpg-sec-515100-confectionery-use-of-non-nutritive-substances-as-ingredients2026-10-13T07:04:22.711Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2dc272d9ab3d09e2ab88e9f844283dd5/investigator-responsibilities-safety-reporting-for-investigational-drugs-and-devices-guidance-for-in2026-10-13T07:04:22.711Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1b8288b56d2d90e7f0dc810d5072f13a/dissolution-testing-of-immediate-release-solid-oral-dosage-forms2026-10-13T07:04:22.196Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2cc51b3c0e9dd228642e9943511a0d3e/cvm-gfi-252-small-entity-compliance-guide-antimicrobial-animal-drug-sales-and-distribution-reporting2026-10-13T07:04:19.365Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2d1ebc4bea14f609b437420638335943/cpg-sec-525325-cumin-seed-adulteration-with-sand-and-grit2026-10-13T07:04:19.365Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2d5683469e66d317d7610eb05d99b447/s2b-genotoxicity-a-standard-battery-for-genotoxicity-testing-of-pharmaceuticals2026-10-13T07:04:19.365Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2018d8b9ef7beadbcd5e46202449b43c/requalification-method-for-reentry-of-blood-donors-deferred-because-of-reactive-test-results-for-ant2026-10-13T07:04:19.139Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2034d7add48f43c3b31682f5c5a7f529/non-clinical-and-clinical-investigation-of-devices-used-for-the-treatment-of-benign-prostatic-hyperp2026-10-13T07:04:19.139Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_1600/16002026-10-13T07:04:17.428Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2c3d8c53108df46a764d40f16e6bedd1/clinical-evaluation-of-antiepileptic-drugs-adults-and-children2026-10-13T07:04:16.094Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2c714a7ed31842f43f792370be98e893/head-lice-infestation-developing-drugs-for-topical-treatment-guidance-for-industry2026-10-13T07:04:16.094Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2c81a57448420d3f177bcf448beee908/public-availability-of-lists-of-retail-consignees-to-effectuate-certain-human-and-animal-food-recall2026-10-13T07:04:16.094Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_1500/15002026-10-13T07:04:13.545Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1b16fe376d36cd2b44a0038b9b41b3f6/questions-and-answers-on-current-good-manufacturing-practices-for-drugs2026-10-13T07:04:12.430Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1b19eca4eb895bc84f9e86c294068587/acne-vulgaris-establishing-effectiveness-of-drugs-intended-for-treatment2026-10-13T07:04:12.430Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1b20e4cb352a0221ede4610958420fdd/safety-considerations-for-container-labels-and-carton-labeling-design-to-minimize-medication-errors2026-10-13T07:04:12.430Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2bfd37712354927e2e85f5d38d36d396/biosimilars-and-interchangeable-biosimilars-licensure-for-fewer-than-all-conditions-of-use-for-which2026-10-13T07:04:12.063Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_1400/14002026-10-13T07:04:09.122Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1fca025f8488f82ee808a56215d7a1fa/nonclinical-safety-evaluation-of-pediatric-drug-products2026-10-13T07:04:05.266Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1ac74bd7b032a70aecf6e831267ac143/pediatric-rare-diseases-a-collaborative-approach-for-drug-development-using-gaucher-disease-as-a-mod2026-10-13T07:04:04.616Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1b0f8025dc317c29843b204fe10aedfb/adequate-and-appropriate-donor-screening-tests-for-hepatitis-b-hepatitis-b-surface-antigen-hbsag-ass2026-10-13T07:04:04.616Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2b8076872b7ef771df09e7000560d7ee/review-and-update-of-device-establishment-inspection-processes-and-standards-guidance-for-industry2026-10-13T07:04:01.393Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2ba18f12162c3f7df043894623252e21/180-day-exclusivity-when-multiple-andas-are-submitted-on-the-same-day2026-10-13T07:04:01.393Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_1300/13002026-10-13T07:04:00.730Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1fbc72a2d623c7cd22880f8140594e1d/repeal-of-section-507-of-the-federal-food-drug-and-cosmetic-act-12026-10-13T07:03:59.394Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0a83bf5da447ce11855dd1b24c49732b/cpg-sec-555300-foods-except-dairy-products-adulteration-with-salmonella2026-10-13T07:03:59.018Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0ab5edf10d365565a7f2039eae6b01e1/the-use-of-mechanical-calibration-of-dissolution-apparatus-1-and-2-current-good-manufacturing-practi2026-10-13T07:03:59.018Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0aee968ba84ab90c869aebe29582a668/expedited-programs-for-serious-conditions-or-drugs-and-biologics2026-10-13T07:03:59.018Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1a18d0577540a9fb5aff9b2bae5d8f1f/final-in-vivo-bioavailability-bioequivalence-studies-analytical2026-10-13T07:03:58.237Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--19e473685e57bde2d547c017d3f8c71c/internetsocial-media-platforms-with-character-space-limitations-presenting-risk-and-benefit-informat2026-10-13T07:03:52.601Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--19e82a73ab854f3793fe68178cc5404d/cvm-gfi-95-vich-gl12-effectiveness-of-anthelmintics-specific-recommendations-for-bovines2026-10-13T07:03:52.601Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--19e9f7bf472ba2e7cc60be13bbbbe0d5/e11-clinical-investigation-of-medicinal-products-in-the-pediatric-population2026-10-13T07:03:52.601Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1f3dc5da9a8e679ce2ae47b1b9a8ee15/bacterial-vaginosis-developing-drugs-for-treatment-guidance-for-industry2026-10-13T07:03:51.565Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2b6ef6f546e8ab1471bd9ce9644583ec/special-protocol-assessment-guidance-for-industry2026-10-13T07:03:51.044Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0a4fe8e6715e15d3cc14bddaf515b700/andas-stability-testing-of-drug-substances-and-products-questions-and-answers2026-10-13T07:03:49.791Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_1200/12002026-10-13T07:03:49.310Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1958f48989867cf5bf080b409c1c4602/severely-debilitating-or-life-threatening-hematologic-disorders-nonclinical-development-of-pharmaceu2026-10-13T07:03:48.033Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--19627498d998d4d9fe0f94fe709952c7/sample-who-certificate-for-quality-of-a-pharmaceutical-product2026-10-13T07:03:48.033Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--19b8c0aa3e9796e3f0463fed2d66562f/recommendations-for-blood-establishments-training-of-back-up-personnel-assessment-of-blood-donor-sui2026-10-13T07:03:48.033Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1ed8672cc0fda248c97531570b981142/cpg-sec-540275-draft-crabmeat-fresh-and-frozen-adulteration-with-filth-involving-the-presence-of-esc2026-10-13T07:03:47.958Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1eda8bfad4102a294a912be424088c3c/cpg-sec-585200-beets-canned-adulteration-with-rot2026-10-13T07:03:47.958Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1eddd0fd06b087fe06e72a003eca6b35/reference-guide-for-the-nonclinical-toxicity-studies-of-antivial-drugs-indicated-for-the-treatment-o2026-10-13T07:03:47.958Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1f00ce99cd08e67c7373025e347e53a3/q4b-annex-4b-microbiological-examination-of-non-sterile-products-tests-for-specified-micro-organisms2026-10-13T07:03:47.958Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0a1c3de88547d9a753a5492cd0b98b38/use-of-serological-tests-to-reduce-the-risk-of-transfusion-transmitted-human-t-lymphotropic-virus-ty2026-10-13T07:03:47.363Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0a47651b5d3de945320217f921516b14/implementation-of-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanyi2026-10-13T07:03:47.363Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2af76d213c360787c5f4b670c4ad7b95/clinical-considerations-for-therapeutic-cancer-vaccines-guidance-for-industry2026-10-13T07:03:46.150Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--18c680b3e9667e15415725075aae2807/chronic-cutaneous-ulcer-and-burn-wounds-developing-products-for-treatment2026-10-13T07:03:44.674Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2aa1446aa8952075feeab282864ee2ee/classification-of-posterior-cervical-screw-systems-small-entity-compliance-guide-guidance-for-indust2026-10-13T07:03:42.507Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2af0ac7edc2e38963a6b29db2b35ba51/cvm-gfi-227-chemistry-manufacturing-and-controls-cmc-technical-section-filing-strategies2026-10-13T07:03:42.507Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--188a844da260600c1af602a958c6f0e7/submission-of-documentation-in-applications-for-parametric-release-of-human-and-veterinary-drug-prod2026-10-13T07:03:39.778Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--18931e6e01307e5f0f34a04dd29de575/standards-development-and-the-use-of-standards-in-regulatory-submissions-reviewed-in-the-center-for2026-10-13T07:03:39.778Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2a9d196e7e49788dbb043ce8b3986328/internetsocial-media-platforms-with-character-space-limitations-presenting-risk-and-benefit-informat2026-10-13T07:03:38.036Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0a11995381e71656c3cf8cbe7b9dbf43/incorporating-voluntary-patient-preference-information-over-the-total-product-life-cycle-guidance-fo2026-10-13T07:03:33.032Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--185aa2317e0f6b5393ae50860e88fdc4/medical-product-communications-that-are-consistent-with-the-fda-required-labeling-questions-and-answ2026-10-13T07:03:32.262Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1ec59b005798fc7c53e09d9d1f9ae948/notifying-fda-of-a-permanent-discontinuance-or-interruption-in-manufacturing-of-a-device-under-secti2026-10-13T07:03:30.890Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_1100/11002026-10-13T07:03:28.989Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2a770d99675073c502c4c36305c6fae5/seventh-of-a-series-of-letters-about-the-act-providing-guidance-on-the-130-day-exclusivity-provision2026-10-13T07:03:28.537Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2a89e8ef39db9d5e2eaad694b214bd7f/peripheral-percutaneous-transluminal-angioplasty-pta-and-specialty-catheters-premarket-notification2026-10-13T07:03:28.537Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0914bdfafd32f87f401f9807aaf3261c/reporting-drug-sample-information-under-section-6004-of-the-affordable-care-act2026-10-13T07:03:23.700Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--096f78e1aae18bb9c634372d77fa9fed/fees-for-human-drug-compounding-outsourcing-facilities-under-sections-503b-and-744k-of-the-fdandc-ac2026-10-13T07:03:23.700Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1e54c58755fffdcb915eeb60e6795f4e/compliance-policy-guide-sec-390200-determination-by-secretary-that-product-fails-to-comply-or-has-de2026-10-13T07:03:23.380Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1eb0058102965bc946cfa4929ec19692/prescription-requirement-under-section-503a-of-the-federal-food-drug-and-cosmetic-act-guidance-for-i2026-10-13T07:03:23.380Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--17e674e1003d3bf11d7b403deafb274c/e11r1-addendum-clinical-investigation-of-medicinal-products-in-the-pediatric-population2026-10-13T07:03:22.285Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1833a26e2bc5e33ad9dcbda3aca27dbb/eosinophilic-esophagitis-developing-drugs-for-treatment-guidance-for-industry2026-10-13T07:03:22.285Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--285968febe61c05cb59b6d24afafee16/cpg-sec-100101-crotalaria-spp-seeds-in-grains2026-10-13T07:03:21.499Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--2942d6b42d87f5d5ebe811402545a3aa/antidepressant-drugs-clinical-evaluation2026-10-13T07:03:21.499Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--295803f963c0311067d39b59736ea774/information-request-and-discipline-review-letters-under-the-prescription-drug-user-fee-act-guidance2026-10-13T07:03:21.499Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--299a509e6bed874c29c71c03ba5b88fa/clarification-of-orphan-designation-of-drugs-and-biologics-for-pediatric-subpopulations-of-common-di2026-10-13T07:03:21.499Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--084a06267ff694defb1b78b72f96f5a7/color-additive-petitions-medical-devices2026-10-13T07:03:20.134Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--08bfd2cd0265f1cfe0bec3b0ced16a2b/compounding-and-repackaging-of-radiopharmaceuticals-by-outsourcing-facilities-guidance-for-industry2026-10-13T07:03:20.134Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--177db5507d90d25fe2ff4f246c9cf542/adverse-event-reporting-for-outsourcing-facilities-under-section-503b-of-the-federal-food-drug-and-c2026-10-13T07:03:17.933Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--17e290952558da19eb6e4585c693020d/implementing-a-collection-program-for-source-plasma-containing-disease-associated-and-other-immunogl2026-10-13T07:03:17.933Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1de35ef42bf15f92c56647dead20d059/expansion-cohorts-use-in-first-in-human-clinical-trials-to-expedite-development-of-oncology-drugs-an2026-10-13T07:03:17.612Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0828a37ed1f49038b0e192380120bc0d/determining-the-extent-of-safety-data-collection-needed-in-late-stage-premarket-and-postapproval-cli2026-10-13T07:03:16.665Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--083d626b816e17401ff60d1a4f2c3f3a/atopic-dermatitis-timing-of-pediatric-studies-during-development-of-systemic-drugs2026-10-13T07:03:16.665Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--27f72a302a26e527f8ec3b31a3983f51/e2e-pharmacovigilance-planning2026-10-13T07:03:16.537Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--27bd6232241567dc7122818d112073cc/use-of-sterile-connecting-devices-in-blood-bank-practices-guidance-for-industry2026-10-13T07:03:10.486Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--27d7606318d23f395cb6231f5be9465e/prussian-blue-drug-products-submitting-a-new-drug-application2026-10-13T07:03:10.486Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1dcb7b160bba5ff4ab0fc92754980866/cvm-gfi-232-vich-gl54-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-g2026-10-13T07:03:09.798Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1de20a5be5f407db4bf8ce1e0f86a849/cvm-gfi-237-oncology-drugs-for-companion-animals2026-10-13T07:03:09.798Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0713820a8c42ae0f24ecd0c77be1a8b5/cvm-gfi-75-vich-gl5-stability-testing-photostability-testing-of-new-veterinary-drug-substances-and-m2026-10-13T07:03:09.354Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--07a5a26328a6f9bef3a448359f26b3b5/clinical-lactation-studies-considerations-for-study-design2026-10-13T07:03:09.354Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--171e66e7d6d30ca64903415f06026fe9/consumer-directed-broadcast-advertisements-guidance-for-industry2026-10-13T07:03:06.824Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--17547b02cfa0a4c219f1e0139c8a8fbd/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-for-treatment2026-10-13T07:03:06.824Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--066c8eecd32c6ed1b73e72858ab0f44d/wholesale-distributor-verification-requirement-for-saleable-returned-drug-productcompliance-policy-g2026-10-13T07:03:00.745Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--06b99e017a8141145c4c034102375eea/recommended-statement-for-over-the-counter-aspirin-containing-drug-products-labeled-with-cardiovascu2026-10-13T07:03:00.745Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--06c370858eaaacf81523f68c30acc09c/premarketing-risk-assessment-guidance-for-industry2026-10-13T07:03:00.745Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1da4f2627f56056271872dc4bfab6ec5/presenting-risk-information-in-prescription-drug-and-medical-device-promotion2026-10-13T07:02:59.155Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--16f6cc20480275497711ff5f7b117fb1/revised-recommendations-for-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes2026-10-13T07:02:58.287Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--16fd6e68808422fb68c050c087c5a3f7/clinical-investigator-administrative-actions-disqualification-guidance-for-institutional-review-boar2026-10-13T07:02:58.287Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--05d58fed7192335cce034d4c6bc69971/rheumatoid-arthritis-developing-drug-products-for-treatment2026-10-13T07:02:53.500Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0646539ee936976d97d64791dc99f7e4/chronic-rhinosinusitis-with-nasal-polyps-developing-drugs-for-treatment-guidance-for-industry2026-10-13T07:02:53.500Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--16f03ee91052ffdf3bf7921570c5fd8f/e10-choice-of-control-group-and-related-issues-in-clinical-trials2026-10-13T07:02:51.674Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--059f795d970f623f982a5c8a3c6f533d/content-and-format-of-chemistry-manufacturing-and-controls-information-and-establishment-description2026-10-13T07:02:50.175Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1d3dd8ed42d156894b03047a1ae52fe1/cpg-sec-683100-action-levels-for-aflatoxins-in-animal-feeds2026-10-13T07:02:49.120Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1d87e1bd52e4557be14f9fb55d0ce5aa/source-animal-product-preclinical-and-clinical-issues-concerning-the-use-of-xenotransplantation-prod2026-10-13T07:02:49.120Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_1000/10002026-10-13T07:02:48.417Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--16eedf4cc195ad5c8d243d339f970450/policy-clarification-and-premarket-notification-510k-submissions-for-ultrasonic-diathermy-devices-gu2026-10-13T07:02:46.872Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--05125c25205c4f9f442a60f7cc663015/e7-studies-in-support-of-special-populations-geriatrics2026-10-13T07:02:46.716Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r47_100/1002026-10-13T07:02:40.993Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--04861691e8cd23d0c98383127b5eb515/cpg-sec-616100-streptomycin-residues-in-cattle-tissues-withdrawn-7720062026-10-13T07:02:40.589Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--04b5610f487fc7148030b367aca62ec0/reproductive-and-developmental-toxicities-integrating-study-results-to-assess-concerns2026-10-13T07:02:40.589Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--16a8e80235fdd062186b2b42d68644a7/appeal-options-available-to-mammography-facilities-concerning-adverse-accreditation-decisions-suspen2026-10-13T07:02:37.545Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--16b4c8749adc8dcf13db65c525225bf8/regulatory-considerations-for-human-cells-tissues-and-cellular-and-tissue-based-products-minimal-man2026-10-13T07:02:37.545Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1d0c857db642816a168193412314e747/cpg-sec-345100-condoms-defects-criteria-for-direct-reference-seizure2026-10-13T07:02:37.451Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--044b0f81c8bbba47ae77ab7725a885e7/updating-anda-labeling-after-the-marketing-application-for-the-reference-listed-drug-has-been-withdr2026-10-13T07:02:35.151Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--046abc70ba9766203a2510a186d7cdaf/statement-of-policy-foods-derived-from-new-plant-varieties2026-10-13T07:02:35.151Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r46_intro/intro2026-10-13T07:02:34.378Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1d0991591c3bd3a21d3b7aa4e8411184/sponsor-responsibilities-safety-reporting-requirements-and-safety-assessment-for-ind-and-bioavailabi2026-10-13T07:02:30.130Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--15227214ac9a63f27b26eb46d1f0511d/dscsa-implementation-product-tracing-requirements-for-dispensers-compliance-policy-revised-guidance2026-10-13T07:02:28.571Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1567f82e371eb5399d0acca7e5ecac98/s4a-duration-of-chronic-toxicity-testing-in-animals-rodent-and-nonrodent-toxicity-testing2026-10-13T07:02:28.571Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--157fe04ec0dcf2fa5aa10292cfabe772/cpg-sec-585890-tomato-products-adulteration-with-drosophila-fly-eggs-and-maggots2026-10-13T07:02:28.571Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--15a11e06dcea7e650bcdbc6dccbef7a5/cpg-sec-585825-sweet-potatoes-dyeing-of-yellow-and-red-varieties2026-10-13T07:02:28.571Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1643f165d915f5c82b11794517d7a04f/guidance-for-industry-color-additive-petitions-fda-recommendations-for-submission-of-chemical-and-te2026-10-13T07:02:28.571Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--16884b5bf6ddff72f161bdc8ce7cd12f/cpg-sec-585350-corn-husks-for-tamales-adulteration-with-filth2026-10-13T07:02:28.571Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--16a19bd4bddff8add5c212465211640b/submissions-for-postapproval-modifications-to-a-combination-product-approved-under-a-bla-nda-or-pma2026-10-13T07:02:28.571Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--03f9c5e64f08d695ae72173fb352a18e/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-ich-regions-annex-11-capill2026-10-13T07:02:27.818Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--041c96e93e2bc5b23ccaf07e19524fee/requalification-method-for-reentry-of-donors-who-test-hepatitis-b-surface-antigen-hbsag-positive-fol2026-10-13T07:02:27.818Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0428b1602e8bd588fb75f4579b83f111/q4b-annex-4a-microbiological-examination-of-non-sterile-products-microbial-enumeration-tests-general2026-10-13T07:02:27.818Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r46_index/index2026-10-13T07:02:22.322Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--14dbea1eac6905479ef8211dc852f14b/revised-recommendations-for-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes2026-10-13T07:02:21.812Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--14f0712d278c4ba1c3d3d6d16badc3cc/manufacturing-considerations-for-licensed-and-investigational-cellular-and-gene-therapy-products-dur2026-10-13T07:02:21.812Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1cd4eed723ae42fa7553098cd1179bfd/interim-policy-on-compounding-using-bulk-drug-substances-under-section-503b-of-the-federal-food-drug2026-10-13T07:02:21.340Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--035d08bb4c9fdf360bebd77a8bb9b47d/enforcement-policy-regarding-investigational-new-drug-requirements-for-use-of-fecal-microbiota-for-t2026-10-13T07:02:18.731Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--03bbf14e4fc28f5d8fa2e15b6f25a82d/quality-systems-approach-to-pharmaceutical-current-good-manufacturing-practice-regulations2026-10-13T07:02:18.731Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--14dbc231303b3cbd0916a73483969a68/geriatric-information-in-human-prescription-drug-and-biological-product-labeling-guidance-for-indust2026-10-13T07:02:16.720Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--14c01efa7248dd47f40286b8d543ded1/hypertension-developing-fixed-dose-combination-drugs-for-treatment2026-10-13T07:02:10.481Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--14c83db301f310f4719495c5e0436164/cpg-sec-550750-raisins-adulteration-involving-mold-sand-grit-and-insects2026-10-13T07:02:10.481Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--14cdaa4181d3b713849ff75731d6c000/cpg-sec-550050-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-a-toxin2026-10-13T07:02:10.481Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1c912bd784e89558f062d916299e02d1/applying-human-factors-and-usability-engineering-to-medical-devices-guidance-for-industry-and-food-a2026-10-13T07:02:03.768Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--13ebfbe8fdb7c0e46fd8099abf149de1/cpg-sec-540370-fish-and-fishery-products-decomposition2026-10-13T07:02:01.698Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--143aa6b8fb1e72069ca5754b0f3e78e2/cvm-gfi-91-vich-gl8-r-stability-testing-for-medicated-premix-or-type-a-medicated-article-revision-12026-10-13T07:02:01.698Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--147dc1862ea9691cf63d866b7ba08ac5/cvm-gfi-159-vich-gl36-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-g2026-10-13T07:02:01.698Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--13d70953b5b7a22c65cde42dfce48b2f/orange-book-questions-and-answers-guidance-for-industry-guidance-for-industry2026-10-13T07:01:52.798Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1c3e2f2a5ad201e501cea28a83c46378/cvm-gfi-188-data-elements-for-submission-of-veterinary-adverse-event-reports-to-the-center-for-veter2026-10-13T07:01:52.573Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r46_ii/appendix-ii2026-10-13T07:01:48.347Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r46_i/appendix-i2026-10-13T07:01:44.488Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--139f474cf6baf7224d35ba34e8ca1f25/cpg-sec-570375-aflatoxins-in-peanuts-and-peanut-products2026-10-13T07:01:41.399Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0301fa4d75f49ee66e141adf2aaf6314/guidance-for-industry-what-you-need-to-know-about-prior-notice-of-imported-food-shipments2026-10-13T07:01:40.973Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0304bc315638c922f4e3f614d90284e2/guidance-for-industry-preparing-a-color-additive-petition-for-submission-to-the-center-for-food-safe2026-10-13T07:01:40.973Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r46_900/9002026-10-13T07:01:39.313Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1be3024e0422bbee7ea209640b6003b7/soft-hydrophilic-daily-wear-contact-lenses-performance-criteria-for-safety-and-performance-based-pat2026-10-13T07:01:39.066Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1c3cbf22706466bbfe2fa36ba3e87165/formal-dispute-resolution-scientific-and-technical-issues-related-to-pharmaceutical-cgmp2026-10-13T07:01:39.066Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--12fcd9a49a6285119920a782cfd6fb40/definitions-of-suspect-product-and-illegitimate-product-for-verification-obligations-under-the-drug2026-10-13T07:01:36.100Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--13517103f17fe24fbccd3db10f54b0c4/critical-path-innovation-meetings2026-10-13T07:01:36.100Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--12cbd585210f7ff1062a2b014e0997d1/nonprescription-sunscreen-drug-products-safety-and-effectiveness-data2026-10-13T07:01:32.257Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--12c261732a22d21440a1430fb7cc8009/abuse-deterrent-opioids-evaluation-and-labeling2026-10-13T07:01:22.565Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--129e0cb0e46f4a6eb86e50eeb54f5d28/patient-counseling-information-section-of-labeling-for-human-prescription-drug-and-biological-produc2026-10-13T07:01:17.212Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--12adf66457726623096ac1e3800fbfe3/opioid-use-disorder-endpoints-for-demonstrating-effectiveness-of-drugs-for-treatment-guidance-for-in2026-10-13T07:01:17.212Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--02bc9965739293a5466cd2a8afbc4e28/cvm-gfi-206-vich-gl47-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in2026-10-13T07:01:15.559Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--02f175270dcdf2b9a5f01605ffff60d2/cvm-gfi-268-adaptive-and-other-innovative-designs-for-effectiveness-studies-of-new-animal-drugs2026-10-13T07:01:15.559Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--120103e89bbd1587b1ebe1b6161d9ff9/uncomplicated-urinary-tract-infections-developing-drugs-for-treatment-guidance-for-industry2026-10-13T07:01:14.638Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--12579a6d2857de47452cc2cb7eeeb1ae/guidance-for-industry-fish-and-fishery-products-hazards-and-controls2026-10-13T07:01:14.638Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1261e43bcb9adff8cb063c2dbbd72688/oncology-therapeutic-radiopharmaceuticals-nonclinical-studies-and-labeling-recommendations-guidance2026-10-13T07:01:14.638Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r46_800/8002026-10-13T07:01:13.092Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--02b0bcd754be27f9d079ea96cf7917fb/manufacturing-biological-intermediates-and-biological-drug-substances-using-spore-forming-microorgan2026-10-13T07:01:11.731Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--11e174860659e54ab33d9d3ae986759b/early-clinical-trials-with-live-biotherapeutic-products-chemistry-manufacturing-and-control-informat2026-10-13T07:01:10.514Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0277d49486c8ae91d8f3e828ab7fe9b3/patient-focused-drug-development-collecting-comprehensive-and-representative-input2026-10-13T07:01:06.955Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--114c789f174ee242395523b06d43945d/covid-19-developing-drugs-and-biological-products-for-treatment-or-prevention-guidance-for-industry2026-10-13T07:01:04.529Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0261e1d7ffe7ee48ab78c9745aa9895e/e9r1-statistical-principles-for-clinical-trials-addendum-estimands-and-sensitivity-analysis-in-clini2026-10-13T07:00:57.080Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--1132d16b9477278f6ead5010205d9e64/requalification-of-donors-previously-deferred-for-a-history-of-viral-hepatitis-after-the-11th-birthd2026-10-13T07:00:56.945Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--113c0497946be27667506627a8cf5faf/considerations-for-developmental-toxicity-studies-for-preventive-and-therapeutic-vaccines-for-infect2026-10-13T07:00:56.945Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--025a836f1a7a3b90eb56545051c462fa/nonclinical-evaluation-of-the-immunotoxic-potential-of-pharmaceuticals2026-10-13T07:00:52.504Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--106798f0a67a7235c0aad1332f8ecaca/human-gene-therapy-for-rare-diseases-guidance-for-industry2026-10-13T07:00:51.921Z https://staging.app.omnilex.ai/en/sources/legislation/us-uspto-mpep--archived-e3r46_700/7002026-10-13T07:00:49.392Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--105d7420baa8a600034b7088144a95b5/q2r1-validation-of-analytical-procedures-text-and-methodology-guidance-for-industry-guidance-for-ind2026-10-13T07:00:47.467Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--023c6d7d900490712bd307eb1c08c401/product-title-and-initial-us-approval-in-the-highlights-of-prescribing-information-for-human-prescri2026-10-13T07:00:36.641Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--101d7bdf649cd8e12302a5f438c5e26b/migraine-developing-drugs-for-acute-treatment2026-10-13T07:00:35.105Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--102b1117539055cd7b2edc80dd6c4efd/m4-organization-of-the-common-technical-document-for-the-registration-of-pharmaceuticals-for-human-u2026-10-13T07:00:35.105Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--022d5cbdc7ba55ab43cdd6d359699367/considerations-for-use-of-histopathology-and-its-associated-methodologies-to-support-biomarker-quali2026-10-13T07:00:29.351Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0f57731a349fb09d765460c953992f6b/pdes-for-triethylamine-and-for-methylisobutylketone2026-10-13T07:00:27.858Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0fbcb00be58fd33e95e748c12ffde17f/cpg-sec-545400-pottery-ceramics-import-and-domestic-cadmium-contamination2026-10-13T07:00:27.858Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0fd99085a2600ba8befcd17a8f6594a6/recommendations-for-screening-testing-and-management-of-blood-donors-and-blood-and-blood-components2026-10-13T07:00:27.858Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--01b1bb46d42ef6ad06bd711f71e9a4e2/potassium-iodide-ki-in-radiation-emergencies-questions-and-answers2026-10-13T07:00:24.724Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--01eb7a2a7583b8d6a18b57f95bc3d188/cvm-gfi-89-vich-gl6-eias-for-veterinary-medicinal-products-phase-i2026-10-13T07:00:24.724Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--012f20755eb9934fc94ac58118f55920/complicated-urinary-tract-infections-developing-drugs-for-treatment2026-10-13T07:00:19.767Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--00c3fa82834a15db3e5b72ab4ad7741c/drug-abuse-and-dependence-section-of-labeling-for-human-prescription-drug-and-biological-products-co2026-10-13T07:00:16.050Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0097980243edd91094de0391cbbefffa/cpg-sec-515750-cocoa-beans-adulteration-by-mold-insect-infestation-and-mammalian-excreta2026-10-13T07:00:12.119Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--00b053288e0105aca21062ffe14aba48/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and-biologi2026-10-13T07:00:12.119Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--000ee15d4e81963ca9770b286ebfb2cc/labeling-of-nonprescription-human-drug-products-marketed-without-an-approved-application-as-required2026-10-13T07:00:02.976Z https://staging.app.omnilex.ai/en/sources/legislation/us-fda-guidance--0051586abf60a3d5326b860694e186aa/enrichment-strategies-for-clinical-trials-to-support-approval-of-human-drugs-and-biological-products2026-10-13T07:00:02.976Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623009/irs-written-determination-2026230092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623010/irs-written-determination-2026230102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623012/irs-written-determination-2026230122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623014/irs-written-determination-2026230142026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623017/irs-published-taxpayer-determination-letter-2026230172026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623018/irs-published-taxpayer-determination-letter-2026230182026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623019/irs-published-taxpayer-determination-letter-2026230192026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623020/irs-published-taxpayer-determination-letter-2026230202026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623021/irs-published-taxpayer-determination-letter-2026230212026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202623022/irs-written-determination-2026230222026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202624001/irs-written-determination-2026240012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202624002/irs-written-determination-2026240022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202624004/irs-written-determination-2026240042026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202624006/irs-written-determination-2026240062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202624007/irs-written-determination-2026240072026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202624008/irs-published-taxpayer-determination-letter-2026240082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202624009/irs-published-taxpayer-determination-letter-2026240092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202624010/irs-published-taxpayer-determination-letter-2026240102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625001/irs-written-determination-2026250012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625002/irs-written-determination-2026250022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625003/irs-written-determination-2026250032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625004/irs-written-determination-2026250042026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625005/irs-written-determination-2026250052026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625006/irs-written-determination-2026250062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625007/irs-written-determination-2026250072026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625008/irs-written-determination-2026250082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625009/irs-written-determination-2026250092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625010/irs-written-determination-2026250102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625011/irs-written-determination-2026250112026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625012/irs-written-determination-2026250122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625013/irs-written-determination-2026250132026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625015/irs-written-determination-2026250152026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625016/irs-written-determination-2026250162026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625017/irs-written-determination-2026250172026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625018/irs-written-determination-2026250182026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625019/irs-written-determination-2026250192026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625020/irs-written-determination-2026250202026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625024/irs-published-taxpayer-determination-letter-2026250242026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625027/irs-published-taxpayer-determination-letter-2026250272026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625028/irs-published-taxpayer-determination-letter-2026250282026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625029/irs-published-taxpayer-determination-letter-2026250292026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202625030/irs-published-taxpayer-determination-letter-2026250302026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626001/irs-written-determination-2026260012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626002/irs-written-determination-2026260022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626003/irs-written-determination-2026260032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626004/irs-written-determination-2026260042026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626005/irs-written-determination-2026260052026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626006/irs-published-taxpayer-determination-letter-2026260062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626007/irs-published-taxpayer-determination-letter-2026260072026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626008/irs-published-taxpayer-determination-letter-2026260082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626009/irs-published-taxpayer-determination-letter-2026260092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626010/irs-published-taxpayer-determination-letter-2026260102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626012/irs-published-taxpayer-determination-letter-2026260122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626013/irs-published-taxpayer-determination-letter-2026260132026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202626014/irs-published-taxpayer-determination-letter-2026260142026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627001/irs-written-determination-2026270012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627002/irs-written-determination-2026270022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627003/irs-written-determination-2026270032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627004/irs-written-determination-2026270042026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627006/irs-written-determination-2026270062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627008/irs-written-determination-2026270082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627009/irs-written-determination-2026270092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627010/irs-written-determination-2026270102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627011/irs-written-determination-2026270112026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627012/irs-written-determination-2026270122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627013/irs-written-determination-2026270132026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627014/irs-published-taxpayer-determination-letter-2026270142026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627015/irs-published-taxpayer-determination-letter-2026270152026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627016/irs-published-taxpayer-determination-letter-2026270162026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627017/irs-published-taxpayer-determination-letter-2026270172026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627018/irs-published-taxpayer-determination-letter-2026270182026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627019/irs-published-taxpayer-determination-letter-2026270192026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627021/irs-published-taxpayer-determination-letter-2026270212026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627022/irs-published-taxpayer-determination-letter-2026270222026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627023/irs-published-taxpayer-determination-letter-2026270232026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202627025/irs-published-taxpayer-determination-letter-2026270252026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628001/irs-written-determination-2026280012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628002/irs-written-determination-2026280022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628005/irs-written-determination-2026280052026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628006/irs-written-determination-2026280062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628007/irs-written-determination-2026280072026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628008/irs-written-determination-2026280082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628010/irs-published-taxpayer-determination-letter-2026280102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628011/irs-published-taxpayer-determination-letter-2026280112026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628012/irs-published-taxpayer-determination-letter-2026280122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628013/irs-published-taxpayer-determination-letter-2026280132026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628014/irs-published-taxpayer-determination-letter-2026280142026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628015/irs-published-taxpayer-determination-letter-2026280152026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628016/irs-published-taxpayer-determination-letter-2026280162026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202628017/irs-published-taxpayer-determination-letter-2026280172026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629001/irs-written-determination-2026290012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629002/irs-written-determination-2026290022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629003/irs-written-determination-2026290032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629005/irs-written-determination-2026290052026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629006/irs-written-determination-2026290062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629007/irs-written-determination-2026290072026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629008/irs-written-determination-2026290082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629009/irs-written-determination-2026290092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629010/irs-written-determination-2026290102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629012/irs-written-determination-2026290122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629014/irs-written-determination-2026290142026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629015/irs-published-taxpayer-determination-letter-2026290152026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629016/irs-published-taxpayer-determination-letter-2026290162026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629017/irs-published-taxpayer-determination-letter-2026290172026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629018/irs-published-taxpayer-determination-letter-2026290182026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629019/irs-published-taxpayer-determination-letter-2026290192026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629020/irs-published-taxpayer-determination-letter-2026290202026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629021/irs-published-taxpayer-determination-letter-2026290212026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629023/irs-published-taxpayer-determination-letter-2026290232026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629024/irs-published-taxpayer-determination-letter-2026290242026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629025/irs-published-taxpayer-determination-letter-2026290252026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629026/irs-published-taxpayer-determination-letter-2026290262026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202629027/irs-published-taxpayer-determination-letter-2026290272026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630001/irs-written-determination-2026300012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630002/irs-written-determination-2026300022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630003/irs-written-determination-2026300032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630004/irs-written-determination-2026300042026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630005/irs-written-determination-2026300052026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630006/irs-written-determination-2026300062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630007/irs-written-determination-2026300072026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630008/irs-written-determination-2026300082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630009/irs-written-determination-2026300092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630010/irs-written-determination-2026300102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630011/irs-written-determination-2026300112026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630012/irs-published-taxpayer-determination-letter-2026300122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630013/irs-published-taxpayer-determination-letter-2026300132026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630014/irs-published-taxpayer-determination-letter-2026300142026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630015/irs-published-taxpayer-determination-letter-2026300152026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630017/irs-published-taxpayer-determination-letter-2026300172026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630020/irs-published-taxpayer-determination-letter-2026300202026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630021/irs-published-taxpayer-determination-letter-2026300212026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630022/irs-published-taxpayer-determination-letter-2026300222026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630023/irs-published-taxpayer-determination-letter-2026300232026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630024/irs-published-taxpayer-determination-letter-2026300242026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630025/irs-published-taxpayer-determination-letter-2026300252026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630026/irs-published-taxpayer-determination-letter-2026300262026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202630027/irs-published-taxpayer-determination-letter-2026300272026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631001/irs-written-determination-2026310012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631002/irs-written-determination-2026310022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631003/irs-written-determination-2026310032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631004/irs-written-determination-2026310042026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631005/irs-written-determination-2026310052026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631006/irs-written-determination-2026310062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631007/irs-written-determination-2026310072026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631008/irs-written-determination-2026310082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631009/irs-written-determination-2026310092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631010/irs-published-taxpayer-determination-letter-2026310102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631011/irs-published-taxpayer-determination-letter-2026310112026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631012/irs-published-taxpayer-determination-letter-2026310122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631013/irs-published-taxpayer-determination-letter-2026310132026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631014/irs-published-taxpayer-determination-letter-2026310142026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631015/irs-published-taxpayer-determination-letter-2026310152026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631016/irs-published-taxpayer-determination-letter-2026310162026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631017/irs-published-taxpayer-determination-letter-2026310172026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202631018/irs-published-taxpayer-determination-letter-2026310182026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632001/irs-written-determination-2026320012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632003/irs-written-determination-2026320032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632005/irs-written-determination-2026320052026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632008/irs-written-determination-2026320082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632009/irs-written-determination-2026320092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632010/irs-written-determination-2026320102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632011/irs-written-determination-2026320112026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632012/irs-written-determination-2026320122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632013/irs-written-determination-2026320132026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632014/irs-written-determination-2026320142026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632015/irs-written-determination-2026320152026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632016/irs-written-determination-2026320162026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632017/irs-written-determination-2026320172026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632018/irs-written-determination-2026320182026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632019/irs-written-determination-2026320192026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632020/irs-written-determination-2026320202026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632021/irs-written-determination-2026320212026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632023/irs-written-determination-2026320232026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632024/irs-published-taxpayer-determination-letter-2026320242026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632025/irs-published-taxpayer-determination-letter-2026320252026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202632026/irs-published-taxpayer-determination-letter-2026320262026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202633001/irs-written-determination-2026330012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202633003/irs-written-determination-2026330032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202633006/irs-written-determination-2026330062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202633007/irs-written-determination-2026330072026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202633009/irs-written-determination-2026330092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202633012/irs-published-taxpayer-determination-letter-2026330122026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634001/irs-written-determination-2026340012026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634002/irs-written-determination-2026340022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634003/irs-written-determination-2026340032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634004/irs-written-determination-2026340042026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634005/irs-written-determination-2026340052026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634006/irs-written-determination-2026340062026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634007/irs-written-determination-2026340072026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634008/irs-written-determination-2026340082026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634009/irs-written-determination-2026340092026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634010/irs-written-determination-2026340102026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634015/irs-published-taxpayer-determination-letter-2026340152026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634016/irs-published-taxpayer-determination-letter-2026340162026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634019/irs-published-taxpayer-determination-letter-2026340192026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202634020/irs-published-taxpayer-determination-letter-2026340202026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202635002/irs-written-determination-2026350022026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202635003/irs-written-determination-2026350032026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202635004/irs-written-determination-2026350042026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202635005/irs-written-determination-2026350052026-10-13T06:59:50.967Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607003/irs-written-determination-2026070032026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607004/irs-written-determination-2026070042026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607005/irs-written-determination-2026070052026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607006/irs-written-determination-2026070062026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607007/irs-written-determination-2026070072026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607009/irs-written-determination-2026070092026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607010/irs-written-determination-2026070102026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607012/irs-written-determination-2026070122026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607013/irs-written-determination-2026070132026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607014/irs-written-determination-2026070142026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607015/irs-written-determination-2026070152026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607016/irs-written-determination-2026070162026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607018/irs-written-determination-2026070182026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607019/irs-written-determination-2026070192026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607020/irs-written-determination-2026070202026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607021/irs-written-determination-2026070212026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607023/irs-published-taxpayer-determination-letter-2026070232026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202607024/irs-published-taxpayer-determination-letter-2026070242026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609001/irs-written-determination-2026090012026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609003/irs-written-determination-2026090032026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609004/irs-written-determination-2026090042026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609005/irs-written-determination-2026090052026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609006/irs-written-determination-2026090062026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609007/irs-written-determination-2026090072026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609008/irs-written-determination-2026090082026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609009/irs-written-determination-2026090092026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609010/irs-written-determination-2026090102026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609011/irs-written-determination-2026090112026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609012/irs-written-determination-2026090122026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609014/irs-written-determination-2026090142026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202609015/irs-written-determination-2026090152026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610002/irs-written-determination-2026100022026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610003/irs-written-determination-2026100032026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610004/irs-written-determination-2026100042026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610006/irs-written-determination-2026100062026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610007/irs-written-determination-2026100072026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610008/irs-written-determination-2026100082026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610009/irs-written-determination-2026100092026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610010/irs-written-determination-2026100102026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610011/irs-written-determination-2026100112026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610012/irs-written-determination-2026100122026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610015/irs-written-determination-2026100152026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610016/irs-written-determination-2026100162026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610018/irs-published-taxpayer-determination-letter-2026100182026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610019/irs-published-taxpayer-determination-letter-2026100192026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610020/irs-published-taxpayer-determination-letter-2026100202026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610021/irs-published-taxpayer-determination-letter-2026100212026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202610022/irs-written-determination-2026100222026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611001/irs-written-determination-2026110012026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611003/irs-written-determination-2026110032026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611004/irs-written-determination-2026110042026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611005/irs-written-determination-2026110052026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611006/irs-written-determination-2026110062026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611007/irs-written-determination-2026110072026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611008/irs-written-determination-2026110082026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611010/irs-published-taxpayer-determination-letter-2026110102026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611011/irs-published-taxpayer-determination-letter-2026110112026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611012/irs-published-taxpayer-determination-letter-2026110122026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611013/irs-published-taxpayer-determination-letter-2026110132026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611014/irs-published-taxpayer-determination-letter-2026110142026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611015/irs-published-taxpayer-determination-letter-2026110152026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611017/irs-written-determination-2026110172026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611018/irs-written-determination-2026110182026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611019/irs-published-taxpayer-determination-letter-2026110192026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202611020/irs-published-taxpayer-determination-letter-2026110202026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612001/irs-written-determination-2026120012026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612002/irs-written-determination-2026120022026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612003/irs-written-determination-2026120032026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612004/irs-written-determination-2026120042026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612005/irs-written-determination-2026120052026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612006/irs-written-determination-2026120062026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612007/irs-written-determination-2026120072026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612008/irs-written-determination-2026120082026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612009/irs-published-taxpayer-determination-letter-2026120092026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612010/irs-published-taxpayer-determination-letter-2026120102026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202612011/irs-published-taxpayer-determination-letter-2026120112026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202613002/irs-written-determination-2026130022026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202613003/irs-written-determination-2026130032026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202613004/irs-written-determination-2026130042026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202613005/irs-written-determination-2026130052026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202613006/irs-written-determination-2026130062026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202614001/irs-written-determination-2026140012026-10-13T06:59:46.569Z https://staging.app.omnilex.ai/en/sources/legislation/us-irs-private-letter-rulings--202614002/irs-written-determination-2026140022026-10-13T06:59:46.569Z